INDEX

Note: Page numbers in italics indicate figures. Page numbers followed by a “t” indicate tables.

ACAM2000, 125t, 483-489, 486t-487t. See also Smallpox.
Acetaminophen, 145
ACIP. See Advisory Committee on Immunization Practices.
ActHIB (Hib-T), 171t, 189, 342, 343, 344t-345t
cost, 148
Active Bacterial Core surveillance (ABCs), 78
Acute disseminated encephalomyelitis (ADEM), 267
Acyclovir, 517, 520, 535
Ad-hoc committees and task forces, 83
Adacel (Tdap), 65t, 125t, 208, 328t-330t. See also Tdap vaccines.
Adaptive immune system, 19, 20, 24, 27
Additives in vaccines, 256-257, 541
Adenovirus, 301-306
clinical features, 301-302
epidemiology and transmission, 302
immunization program, 302
pathogen, 301
vaccine, 302, 303t
contraindications/precautions, 304-305
immunogenicity/efficacy, 304
recommendations, 303t, 305
safety, 304-305
storage, 122t
Adjuvants, 26, 27, 254-256, 541. See also specific vaccines.
action mechanisms, 28t-29t
alum/aluminum, 26, 28t, 254-256
antigen sparing and, 26
AS01, 29t, 256
AS03, 28t, 273, 403
AS04, 28t, 256
autoimmune/autoinflammatory syndrome (ASIA), 256
CpG 1018, 29t, 256, 362t
MF59, 29t, 256, 403
thimerosal, 262-263
Administration of vaccines, 135-145, 153-180. See also Delivery of vaccines; Recommendations; Vaccine practice.
administration of vaccines, continued
gloves, 110, 136, 144
grace period, 112, 154, 155, 162
interchangeability of vaccines from different manufacturers, 163-164
intervals for vaccinations, 153-162, 156t-161t
accelerated schedules, 155
doses in a series, 155, 163
doses of same vaccine, 155-162
inactivated vaccines, 155
lapse in series and, 163
between live vaccines and antibody-containing blood products, 164-165, 166t-168t
live vaccines not given at the same time, 153, 154
simultaneous administration, 64t, 153-155
minimum age and intervals, 153-163, 156t-161t, 288
multiple vaccines
simultaneous administration of, 64t, 95, 136, 153-155
exceptions, 153
no maximum number of vaccinations in single day, 136
using different sites for, 137, 153
needle type and length, 141, 142, 143t
for persons who have had the disease, 164, 179t
prefilled syringes, 121
routes of administration, 14t, 141-145, 142
errors in, 169-175, 169t
intradermal, 26, 141-145, 142
intramuscular, 141, 142
intranasal, 141, 144
jet injectors, 144-145
needle type and length, 141, 142, 143t
oral, 141, 144
parenteral, 20
subcutaneous, 141, 142, 143t
schedules for. See Schedules.
ten simple rules, 153-169
1. any vaccines can be given on same day, 153-154
2. live vaccines not on same day, 154
3. inactivated vaccines, timing of administration, 155
4. minimum intervals for doses of same vaccine, 155-162
5. minimum ages, 162-163
6. vaccines in a series, 163
7. vaccines from different manufacturers, 163-164
8. person who has already had the disease, 164
9. antibody-containing blood products, 164-165
10. households with pregnant and immunocompromised persons, 165-169
waiting (observation) time after, 145
“when in doubt, vaccinate,” 164
Adolescent immunization, 93-97, 285-286
adolescent platform, 96, 285-286, 300t
early adolescent, 285, 300t
late adolescent, 285-286, 300t
Adolescent immunization, 93-97, 285-286
Adolescent immunization, continued
barriers to immunization, 96-97
coverage rates, 73-77, 76, 387
Denver Health example, 134, 135t
DTap series vs Tdap, 324-326, 335-336
hepatitis B vaccine, 288, 367
HPV vaccine, 288, 292, 380, 381, 387
improving delivery, 134, 135t, 136t-137t
N meningitidis, 291, 434, 435, 436, 444-445, 446t
observation time after immunization, 145, 146
pneumonia vaccine, 495, 496
schedules
  catch-up, 292-293
  routine (for healthy persons), 288-289
  routine young adult, 288-289
  special immunizations, 294t-295t
  standards for, 93-97
  syncope and, 145, 146
Adoptees, international, 218-219, 348, 353
Adult immunization, 97, 285, 296-299. See also Older adults.
  improving rates of, 134, 136t-137t
  at pediatric office visit, 132
  schedules. See also specific vaccines.
    by age group, 296-297
    by medical indication, 298-299
  standards for adults, 97, 98t-99t
  young adult immunization platform, 300t
Adventitious agents, 270-271
Adverse events, 79-83. See also Vaccine Safety Net; specific vaccines.
adverse event following immunization (AEFI), 79, 79t
causality and, 79, 79t, 100, 233
clinical trials and numbers of subjects, 55-56, 57t
clustered anxiety-related, 275-276
contraindications and precautions, 176-177
  screening for, 135, 138t-140t, 241
contraindications/precautions and, 176
  definition of, 79, 79t
effect on recommendations, 236t
genetics and, 45-46
  mandatory reporting requirements, 79, 96, 101, 103t
  on package insert, 62
Reportable Events, 99-101, 106t-109t
Reporting System (VAERS), 79-81, 101-105
unavoidable side effects of vaccines, 101, 235
Advisory Committee on Immunization Practices (ACIP), vi, 63-71, 66
  recommendations, vii, 63-71, 64t-65t, 543
  categories and language, 74t-75t
  GRADE approach, 67-70, 71t
  for pregnancy and breast-feeding, 208
  on simultaneous administration of vaccines, 64t, 154
  working groups, 67
Advocacy organizations, 559t-560t
Affinity maturation, 27
Affordable Care Act (ACA), 84
Affix, 134
Afluria (IIV, influenza), 145, 400t
Age. See also Schedules for immunization.
  definition of, vii
  grace period, 112, 154, 162
  minimum ages for vaccines, 19, 153-163, 156t-161t, 288
Agencies and committees, 54, 66
AIDS. See also HIV.
  polio vaccine not the cause of, 268-269
  response to vaccines and, 183
Alcoholism, vaccinations recommended, 298-299
Allergies, 176, 258-260. See also specific vaccines.
  allergic reactions to vaccine components, 176, 256, 331. See also
  Contraindications and precautions.
  to eggs, 256, 407
  hygiene hypothesis and, 258
  to penicillin, 178t
  severe, 176
Allied Vaccine Group, 559t
Alternative schedules, 232, 257-258
Alum/aluminum salts, 26, 28t, 254-256
American Academy of Family Physicians (AAFP), vii, 285, 543, 558t
American Academy of Pediatrics (AAP), vii, 558t
American College Health Association (ACHA), 558t
American College of Nurse-Midwives, 285
American College of Obstetricians and Gynecologists (ACOG), 285, 558t
American College of Physicians (ACP), 97, 285, 558t
American Immunization Registry Association, 559t
American Medical Association (AMA), 559t
American Nurses Association (ANA), 559t
American Pharmacists Association (APA), 559t
American Public Health Association (APHA), 559t
  Anamnestic response, 23, 26, 27, 31
  Anaphylaxis, 106t-107t, 146-147, 176, 367, 462, 517
  as medical emergency, 146-147
  signs and symptoms of, 146
Animal rule, 59
Animal workers, vaccination of, 111, 226t, 312, 464t
Anogenital warts, 378, 572t
Anthrax, 307-313
  antibiotic therapy, 308
  bioterrorism potential, 307-308, 312
  clinical features, 307
  epidemiology and transmission, 307-308
  immunization program, 308-309
  monoclonal antibodies, 309, 312
  pathogen, 307, 572t
  vaccine, 309, 310t-311t
Anthrax, continued
characteristics and specifics of, 310t
contraindications/precautions, 164, 311
immunogenicity/efficacy, 309
recommendations/schedule, 310t, 312
bioterrorism recommendations, 312
military use, 309, 311, 312
postexposure prophylaxis, 309, 310t, 312
pre-exposure vaccination, 308-309, 310t
safety, 309-311
storage, 122t
trade name (anthrax vaccine adsorbed, AVA), 308-309, 310t-311t
Antibodies, 19-32, 21. See also Immune globulin; Immune response.
action mechanisms and sites, 20, 21
antibody deficiency with normal immunoglobulins, 183
antibody-dependent cell-mediated cytotoxicity, 20, 35
broadly neutralizing, 20
engineered, 19
epitopes, 19, 26
germline, 22
high-affinity, 25, 27
measurement of, 40
neutralization, opsonization, and lysis, 20, 21
passive immunization with, 11, 18-19, 165
persistence of, 30-31
potential inactivation of vaccines, 165
reassortment, 16, 393, 403
T-cell independent, 22
Antivaccinationism, 246-248, 247t, 249t-250t, 261
Antigens, continued
in routine vaccines, 254, 255t, 258
polysaccharide, 17-18, 22-24, 23, 31
hyporesponsiveness to, 22
reassortment, 16, 393, 403
T-cell independent, 22
Asplenia,
Hib vaccination, 343-346
influenza vaccination, 408
N meningitidis, 446t
Apremilast, 199
AS01, 29t, 256
AS03, 28t, 273, 403
AS04, 28t, 256
Aspirin, Reye syndrome and, 138t, 226t, 408, 410, 517
Asplenia, 192, 197-198, 294t, 298-299
Hib vaccination, 343-346
influenza vaccination, 408
Hib vaccination, 343-346
influenza vaccination, 408
Association for Prevention Teaching and Research, 559t
Association of State and Territorial Health Officials, 559t
Asthma, 184, 198, 258, 408, 409
Attenuation of vaccines, 11-16, 12t
altered site of infection, 16
attenuated vaccines, listed, 12t
engineered attenuation, 16
reassortment, 16
serial passage, 11-16, 271
Authority, 234
Autism, 261-263
MMR vaccine and, 261-262
number of antigens and, 258
Omnibus Autism Proceedings, 263
thimerosol and, 262-263
Autoimmunity, 258-260
adjuvants and, 256
autoimmune diseases, 178t, 198, 258-260
HPV and, 386
AVA (anthrax vaccine adsorbed), 308-309, 310t-311t
B cells, 20, 22, 23, 27
activation of, 20, 22, 30-31
bystander activation, 30
B-cell deficiencies, 189-196
B-cell receptor, 20, 23, 31
clonal expansion/proliferation of, 20, 25
differentiation of, 30-31
memory B-cells, 23, 26, 27, 30-31
Bacille Calmette-Guérin (BCG), 16
Bacillus anthracis, 307, 572t. See also Anthrax.
Bacteria. See also specific bacteria.
Active Bacterial Core surveillance system, 78
antibody effects on, 20, 21
attenuation of, 16
viruses vs, 35
BARDA (Biomedical Advanced Research and Development Authority), 62
Barrier defect, 186-187
BCG (Bacille Calmette-Guérin), 16
Behavioral Risk Factor Surveillance System (BRFSS), 77, 561t
Bell’s Palsy, 273
Bexsero. See MenB-4C.
Bill & Melinda Gates Foundation, 559t
Biologics License Application (BLA), 54, 58-59
Biomedical Advanced Research and Development Authority (BARDA), 62
Bioterrorism
anthrax and, 307-308, 312
smallpox and, 47, 482-483
BioThrax, 122t, 309, 310t-311t. See also Anthrax.
Bird flu (influenza A; H5N1). See also Influenza.
Birth defects, 176, 203, 274-275
percentage of all babies born with, 208
rubella and, 421
Birth vaccinations, 212, 288, 360, 366, 543
BLA (Biologics License Application), 54, 58-59
Bleeding diathesis, 226t
Blood transfusion, interval for live vaccines and, 167t
Bloodborne Pathogens Standard, 105-111
Bone marrow (HSCT) transplantation, 202-203, 204t-207t
Books on vaccines, 562t
Booster vaccination, 26-27, 30, 31
Boostrix (Tdap), 65t, 125t, 208, 327, 328t-330t. See also Tdap vaccines.
Bordetella pertussis, 17, 321-322, 323, 572t. See also Pertussis.
Botulism, immune globulin (BabyBig), 167t
Brain damage, pertussis vaccine concerns, 263-264
“Breakthrough therapy” category, 58-59
Breakthrough varicella infection, 511-512
Breast-feeding, 178t, 209, 479, 490t, 528. See also Pregnancy.
live viruses and, 305
BRFSS (Behavioral Risk Factor Surveillance System), 77, 561t
Brighton Collaboration, 82, 559t
Butte County, California (hepatitis A in), 43, 349

Cancer, 377-379, 379
anal, 379, 379
cervical, 377-378, 379, 387
chemotherapy for, 199-200, 369
oral, 378, 379
penile, 378, 379
polio vaccine and, 268
vaginal, 378, 379

Catch-up immunization schedules
children, age 4 months-6 years, 290-291
children, age 7-18 years, 292-293
Causal relationships, 79t, 100, 231-235, 233
CBER, 53-55, 54, 66
CD4, 23, 24, 32, 34, 182
CD8, 32, 34, 182
CD40, 23, 196
CDC. See Centers for Disease Control and Prevention.
Celiac disease, 197, 259-260
Centers for Biologics Evaluation and Research (CBER), 53-55, 54, 66
Centers for Disease Control and Prevention (CDC), 62-63, 66, 558t
disease surveillance, 78
vaccine stockpiles, 89-90, 403
Cerebrospinal fluid. See CSF leaks
Cervarix (HPV2), 380, 381. See also Human papillomavirus.
Cervical cancer, 377-378, 379, 387
Chemotherapy, 199-200, 369
Chickenpox, 164, 484t-485t, 511. See also Varicella.
acyclovir and, 517, 520
differentiating from smallpox, 484t-485t
as nearly eliminated in the U.S., 512
Children. See also Adolescent immunization; Infants.
aspirin therapy and, 408, 410
Childhood Immunization Support Program, 71-72
cocooning strategy, 131, 324
coding for routine visit, 148, 150t-151t
costs of immunization, 84
coverage rates, 73, 76
HIV-infected, 182, 185-189, 343
immunization schedules, 288-293
catch-up, age 4 months-6 years, 290-291
catch-up, age 7-18 years, 292-293
exemptions from, 112-113
financing for, 84-85
grace period, 112, 162
routine immunizations, age 0-18 years, 288-289
safety to, 258
special immunizations, 294t-295t
immunization standards, 93-97
impact of routine childhood vaccination, 43, 52t
National Childhood Vaccine Injury Act, 79, 83, 99-105
observation time after immunization, 145
pain relief for, 145
participation in Immunization Information Systems, 133
school-aged immunization platform, 300t
school-located vaccination, 132
specific vaccines
hepatitis A, 288, 348, 353
hepatitis B, 288, 360, 367, 370t-372t
HPV, 380, 381, 387
influenza, 396-399, 398, 408
Children, continued

MMR, 423, 430
MMRV, 543
N meningitidis, 435, 436
pneumonia, 288, 289, 494-497, 501
polio, 453
Tdap and DTaP, 288, 325, 335
varicella, 518

Task Force on Safer Childhood Vaccines, 83
Vaccines for Children (VFC) Program, 63, 84-85, 86t-87t
Children's Health Insurance Program (CHIP), 88
Children's Hospital of Philadelphia Vaccine Education Center, 559t
Children's Vaccine Program at PATH, 559t

Cholera, 315-319
clinical features, 315
epidemiology and transmission, 315-316
immunization program, 316
pathogen, 315, 572t
vaccine, 316, 318t-319t
contraindications/precautions, 317
engineered attenuation, 16
immunogenicity/efficacy, 317
recommendations, 318t, 319
for travel, 224, 316, 319
safety, 317
storage, 122t
trade name (Vaxchora), 316, 318t-319t

Cholera toxin, 315

Chronic fatigue, 275
Chronic granulomatous disease (CGD), 182, 196
CISA (Clinical Immunization Safety Assessment) Network, 81-82, 559t
Classification of vaccines, 12t-13t
Clinical Immunization Safety Assessment (CISA) Network, 81-82, 559t
Clinical trials, 55-58, 56
for combination vaccines, 541-542
numbers of subjects required, 55-56, 56, 57t
phase 1, 2, 3, and 4 trials, 55-58, 56
Clonal expansion/proliferation, 20, 25
Clostridium tetani, 321, 323, 572t. See also Tétanos.

CoCASA, 134, 561t
Cochlear implants, 184, 408
Cocooning strategy, 131, 324
Coding and billing, 147-148, 150t-151t
CPT codes, 148, 150t-151t
ICD codes, 148, 150t-151t
NDCs (National Drug Codes), 147-148
reimbursement according to antigens delivered, 542
routine infant office visit (example), 148, 150t-151t
College students, vaccination of, 226t, 435, 436, 437, 445, 446t, 518
Combination vaccines, 541-556
adjuvants and excipients in, 541, 547t-548t, 553t-554t
advantages of, 542

Combination vaccines, continued
improved compliance, 155
improved coverage and timeliness, 542
reduction in number of shots, 154, 542
clinical trials for, 541-542
contraindications/precautions, 543
efficacy/immunogenicity, 542
minimum age for, 162-163
minimum intervals for, 162
noninferiority standard, 542
overimmunization, concern about, 543
preference for, 543
production of, 541
recommendations, 543
reimbursement for, 542
safety, 542-543
specific vaccines, 544t-555t, 573t
DTaP-based, 122t, 542-543, 544t-550t
other, 552t-555t
terminology and nomenclature, vii, 572-573t
Common variable immunodeficiency (CVID), 182-183, 189
Communicating about vaccines, 235-242, 238t-239t. See also Concerns about vaccines, addressing.
antivaccinationism, 246-248, 247t, 249t-250t
public harm from, 242-246
biases, 231-234
causality, ideas about, 231-235, 233
cultural cognition/sensitivity, 241
erroneous beliefs, 239-241, 250t
HPV vaccine for adolescents, 388, 389t-390t
human nature and perceptions, 231-235, 233
illusory truth effect, 239
language and meaning, 242, 243t
pitfalls to avoid, 243t
risks vs benefits, 235
sources of information, 238, 240, 246
specific concerns, 252-276
strategies for, 235-242, 238t-239t
vaccine confidence, teaching, 242
vaccine refusal, 242-246, 244
Community education, 134
Community immunity. See Herd immunity.
Community service providers, 227t
Compensation. See Vaccine Injury Compensation Program.
Complement deficiencies, 182, 192, 197, 298-299, 446t
Complement-mediated lysis, 20, 21
Component vaccines, 12t, 17-18
Comprehensive Clinic Assessment Software Application (CoCASA), 134, 561t
Concerns about vaccines, addressing, 231-283
action vs inaction, 231, 234
antivaccinationism, 246-248, 261
Concerns about vaccines, addressing, continued

- emotional appeals and tropes, 246, 247t, 249t
- flawed thinking, 250t
- public harm from, 242-246
- causal relationships, 231-235, 233
- communicating risks and benefits, 231-242
- biases, 231-234
- communication strategies, 235-242, 238t-239t, 389t-390t
- human nature and, 231-235, 233
- language and meaning, 242, 243t
- questionnaires, 241
- risk vs benefit, balancing, 235, 236t, 237t
- safety, meaning of, 235
- sources of information, 238, 240, 246
- conspiracy theories, 234-235
- costs of public concern, 248-252
- cultural cognition/sensitivity and, 241
- risks vs benefits, balancing, 181, 235, 236t, 237t
- sources of information on vaccines, 238, 240, 246
- specific concerns, 252-276
- additives, 256-257
- adjuvants, 254-256
- adventitious agents, 270-271
- AIDS, polio vaccine and, 268-269
- allergies and autoimmune diseases, 256, 258-260
- alternative schedules, 257-258
- autism, 261-263
- Bell's Palsy, 273
- brain damage, pertussis vaccine and, 263-264
- cancer, SV40 contamination and, 268
- chronic fatigue, 275
- clustered anxiety-related adverse events, 275-276
- demyelinating diseases/MS, 266-267
- febrile seizures, 271
- fetal tissue, 260-261
- Guillain-Barré syndrome, 264-266
- immune overload, 253-254
- immune thrombocytopenia, 235, 272-273
- Kawasaki disease, 27
- mad cow disease, 267-268
- miscarriage and birth defects, 208, 274-275
- multiple sclerosis, 266-267
- narcolepsy, 273-274
- natural vs vaccine-induced immunity, 253
- necessity of vaccines, 252-253
- nonspecific negative effects, 260
- polio vaccine, AIDS pandemic and, 268-269
- primary ovarian insufficiency (POI), 276
- rotavirus vaccines and intussusception, 235, 272
- SIDS, 269
- thimerosol, 262-263
- vaccine acceptance, hesitancy, and confidence, 231-235, 232, 233t, 242
- vaccine refusal, 242-246, 244
Cytotoxic T cells (Tc cells), continued
- cross-presentation and, 35, 36
- implications for vaccination, 32-36
- Cytotoxicity, antibody-dependent cell-mediated, 20
- Cytotoxins, 32

Daptacel (DTaP), 122t, 328t-330t. See also DTaP vaccines.

Day care centers
- immunization mandates for, 112-114
- vaccination of workers, 227t, 354-355

Deaths
- from chickenpox, 515
- from influenza, 395-396, 396
- from measles, 420, 423
- from pneumonia, 213, 494
- from rabies, 456
- from rotavirus, 472
- from smallpox, 481
- sudden infant death syndrome (SIDS), 269
- from vaccine-preventable diseases, 97, 396

Defense Medical Surveillance System (DMSS), 82

Deferral of doses, 89, 164-165

Delayed-type hypersensitivity, 176

Delivery of vaccines, 129-135
- documentation of vaccinations received, 129
- immunization coalitions, 134
- Immunization Information Systems (IISs), 133-134
- medical home and immunization neighborhood, 130-132
- missed opportunities, 130, 177
- monitoring, 73-78
- National Immunization Survey (NIS), 73-77, 561t
- other strategies for improving, 134
  - CoCASA, 134
  - community education, 134
  - 4 Pillars Program, 134, 136t-137t
  - reminder, recall, and tracking systems, 130
  - school-located vaccination, 132
  - standing orders, 133

Demyelinating diseases, 264-267

Dendritic cells, 24, 26

Dengue vaccine (Dengvaxia), 12t, 525

Denver Health, adolescent immunization strategies, 134, 135t

Department of Defense (DOD), 66
- Defense Medical Surveillance System, 82

Development of vaccines. See Vaccine development and licensure.

Developmentally disabled, staff of institutions, 227t, 368

Diabetes, 259
- vaccination recommendations, 184, 295t, 298-299, 368

DiGeorge syndrome, 176, 182, 196

Diphtheria, tetanus, and pertussis, 321-339. See also individual entries for Diphtheria, Tetanus, Pertussis.
- clinical features, 322-323

Diphtheria, tetanus, and pertussis, continued
- epidemiology and transmission, 323-324
- immunization programs, 324-326
- pathogens, 321-322, 572t
- vaccines, 326, 328t-330t, 332t-333t
  - administration errors and remedies, 170t-171t
  - characteristics and specifics of, 328t-330t, 332t-333t, 572t
  - combination vaccines, 544t-550t
  - contraindications/precautions, 331-335
  - DTaP-based, 328t-330t, 544t-550t
  - immunogenicity/efficacy, 326-331
  - recommendations, 324-326, 325, 335-336
    - adolescents, 324
    - adult. See Tdap vaccines.
    - children/infants. See DTaP vaccines.
- safety, 331-335
- trade names, 328t, 544t
  - Adacel (Tdap), 328t-330t
  - Boostrix (Tdap), 328t-330t
  - Daptacel (DTaP), 328t-330t
  - Infanrix (DTaP), 328t-330t
- waning immunity, 253, 327

Diphtheria, 321-339. See also Pertussis; Tetanus.
- clinical features, 322
- correlates of protection, 38t
- epidemiology and transmission, 323
- immunization program, 324
- pathogen, 321, 572t
- resurgence of, 324
- vaccines, 326, 328t-330t, 332t-333t, 572t. See also DT; DTaP vaccines; Tdap vaccines.
  - combination vaccines, 542-543, 544t-550t
  - contraindications/precautions, 331-335
  - DTwP replacement by DTaP, 231, 324
  - immunogenicity/efficacy, 326-331
  - recommendations, 324-326, 325, 335-336
  - safety, 331-335
  - schedule, 329t, 332t, 335-336
  - storage, 122t
- trade names, 328t, 332t
  - Adacel (Tdap), 328t-330t
  - Boostrix (Tdap), 328t-330t
  - Daptacel (DTaP), 328t-330t
  - Infanrix (DTaP), 328t-330t
  - Tenivac (Td), 323t-333t
- waning immunity, 253, 327

Diphtheria and Tetanus Toxoids Adsorbed (DT), 332t-333t

Disease dangers of, 235, 237t
- doing nothing about, 231
Disease, continued
elimination of, 46-48, 49t
eradication of, 46-48, 49t, 253
extinction of, 46-47
prevention of, 35, 78, 235
re-emergence of, 248-253
vaccination of persons who have had the disease, 164, 179t, 336

Eradication of disease, 46-48, 49t
power and weather, vaccine storage during, 128t
PREP Act, 105

Emergencies, 128t, 145-147
anaphylaxis, 146-147

Emergencies, 128t, 145-147
anaphylaxis, 146-147

Documentations of vaccines received, 129

Dosing
administration errors, and remedies, 169-175, 169t-174t
correction for errors in, 170t-174t
deferral of doses, 89, 164-165
expired or invalid dose, 120, 141, 155, 169, 170t
Drug users, injecting, 226t, 295t, 353, 354, 368

Disease-modifying antirheumatic drugs (DMARDs), 198-199

Documentation of vaccinations received, 129

DT (diphtheria, tetanus toxoids), 122t, 332t-333t, 335
contraindications/precautions, 334-335

DTaP vaccines, 328t-330t, 544t-550t. See also Diphtheria, tetanus, and pertussis.
administration errors and remedies, 170t-171t
combination vaccines, 122t, 542-543, 544t-550t
Kinrix (DTaP-IPV), 122t, 544t-550t
Pediarix (DTaP-HepB-IPV), 64t, 544t-550t
Pentacel (DTaP-IPV/Hib), 122t, 453, 544t-550t
Quadrixel (DTaP-IPV), 122t, 544t-550t
Vaxelis (DTaP-IPV-Hib-HepB), 122t, 544t-550t
contraindications/precautions, 331-334, 542
DTwP replaced by, 231, 324
immunogenicity/efficacy, waning immunity and, 253, 327
minimum ages and intervals, 156t, 162, 288
recommendations, 325, 329t, 335
same product for entire series, 163, 164
wound management, 338t-339t
safety, 331-335
carrier-induced epitopic suppression, 541
epitope spread, 26

Epilepsy and prevention of vaccine-preventable diseases (“Pink Book”), 67

Erosins and contaminants, 176, 256-257, 541. See also specific vaccines.
Exemptions from immunization requirements, 112-114

Disease-modifying antirheumatic drugs (DMARDs), 198-199

Dysentery, 115, 164, 179t, 243, 337

Echeneis naucrates vaccine, 12t

Ecoliuzumab, 197

Effectiveness of vaccines, vs efficacy, 58

Efficacy, 36. See also specific vaccines.
clinical trials for, 55-58
correlates of protection, 36-41, 38t-39t
effectiveness vs, 58
ethical studies and Animal Rule, 59

Eggs
allergy to, 256, 407
egg-free influenza vaccines, 400t, 403
serial passage in, 11

Elimination of disease, 46-48, 49t

Emergency preparedness, 62, 105, 145-147
for anaphylactic reactions, 146-147
PREP Act (Public Readiness and Emergency Preparedness), 105, 489

End-stage renal disease, vaccinations in, 368

Encephalitis
Japanese encephalitis, 413-418
measles and, 420
postvaccination (vaccine-associated neurotropic disease), 527
smallpox and, 481
yellow fever vaccine and, 529

Encephalopathy, 106t, 263-264
acute, as vaccine contraindication, 176
DTaP/Tdap vaccine and, 176, 263-264, 331, 334

End-stage renal disease, vaccinations in, 298-299, 368

End-stage renal disease, vaccinations in, 298-299, 368

Engerix-B (Hep-B vaccine), 123t, 361, 362t-365t, 367

Engineered antibodies, 19
Engineered attenuation, 16
Engineered subunits, 12t, 18

Enteric-coated tablets, 16, 302

Epidemics/pandemics
compensation for vaccination injuries due to, 489
preparedness for, 62

Epidemiology and Prevention of Vaccine-Preventable Diseases (“Pink Book”), 67

Epitopes, 19
carrier-induced epitopic suppression, 541
epitope spread, 26

Eradication of disease, 46-48, 49t, 253

Errors in administration of vaccines, 169-175, 169t
corrections for, 170t-174t

Ethics
alternative schedules and, 257-258
arguments for vaccination, 113-114, 234, 242-246
ethical studies of vaccine efficacy, 59
public harm from vaccine refusal, 242-246, 244
vaccination as civic duty, 245
vaccination as social norm, 239

Exemptions from immunization requirements, 112-114

Eggs
allergy to, 256, 407
egg-free influenza vaccines, 400t, 403
serial passage in, 11

Elephantiasis
Japanese encephalitis, 413-418
measles and, 420
postvaccination (vaccine-associated neurotropic disease), 527
smallpox and, 481
yellow fever vaccine and, 529

Engerix-B (Hep-B vaccine), 123t, 361, 362t-365t, 367

Engineered antibodies, 19

Engineered attenuation, 16

Engineered subunits, 12t, 18

Enteric-coated tablets, 16, 302

Epidemics/pandemics
compensation for vaccination injuries due to, 489
preparedness for, 62

Epidemiology and Prevention of Vaccine-Preventable Diseases (“Pink Book”), 67

Epitopes, 19
carrier-induced epitopic suppression, 541
epitope spread, 26

Eradication of disease, 46-48, 49t, 253

Errors in administration of vaccines, 169-175, 169t
corrections for, 170t-174t

Ethics
alternative schedules and, 257-258
arguments for vaccination, 113-114, 234, 242-246
ethical studies of vaccine efficacy, 59
public harm from vaccine refusal, 242-246, 244
vaccination as civic duty, 245
vaccination as social norm, 239

Exemptions from immunization requirements, 112-114

588

589
Extinction of disease, 46-47
Extrafollicular reaction, 22-24, 23

Families Fighting Flu, 559t
FDA. See Food and Drug Administration (FDA).
Fear of vaccines, harm from, 231, 242-246
Febrile seizures, 145, 154, 426, 542, 543
vaccine safety and, 271
Fetal tissue in vaccine manufacture, 260-261
Fever, 145
Filamentous hemagglutinin (FHA), 17, 321, 326, 328t
Fimbriae (FIM), 17, 321, 326, 328t
Financing of immunization, 83-88, 94
Medicare/Medicaid, 88
public sector funds, 84-88, 94, 148
Section 317 funds, 85-88, 94
state and local funds, 88
universal purchase states, 88
Vaccines for Children (VFC) Program, 84-85
Flu. See Influenza.
Fluad, 400t, 403
Fluarix (IIV, influenza), 171t, 400t
Flublok (rIIV) (egg-free influenza vaccine), 400t, 403
Flucelvax (ccIIV), 400t, 403
Flulaval, 171t, 400t
Fluzone (IIV, influenza), 401t
Fluzone High-Dose (hdIIV, influenza), 213-214, 399, 401t
Food and Drug Administration (FDA), 53, 54, 66, 558t
vaccine development and licensure, 53-55, 54, 68t, 80
Food handlers, vaccination of, 226t, 355
Foresters, vaccination of, 226t
Formaldehyde, 17, 257
4 Pillars Program, 134, 136t-137t
Freezer, storage of vaccines in, 121-127, 125t-126t
Gardasil (HPV4), 380-386, 381
Gardasil 9 (HPV9), 123t, 380-388, 384t-385t. See also Human papillomavirus.
Gastroenteritis. See Rotavirus.
Gelatin, 256. See also specific vaccines.
General Best Practice Guidelines, 67, 177, 181
Generations United, 559t
Genetic engineering, 12t, 18
Genetics of vaccine responses, 45-46
polymorphisms, 45-46
somatic hypermutation, 25
Genital warts, 378, 379, 572t
Germinal center reaction, 23, 24-32
heterotypic (cross-protective) responses, 27-30, 36
homotypic responses, 27
implications for vaccination, 26-32
Germline antibodies, 22
Global Alliance for Vaccines and Immunization, 560t
Gloves, 110, 136, 144
Good Clinical Practice (GCP), 54, 55
Good Laboratory Practices (GLPs), 54, 55
Good Manufacturing Practices (GMPs), 53-55, 54
Good Pharmacovigilence Practices (GPPs), 58
Governmental agencies and committees, 54, 66, 558t
Grace period, 112, 154, 155, 162
special grace period, 162
GRADE approach, 67-70, 71t
Guillain-Barré syndrome, 109t, 260, 264-266
as contraindication/precaution
for DTaP/Tdap vaccines, 334
for influenza vaccines, 407, 408
for N meningitidis vaccines, 444
human papilloma vaccine and, 266, 386
influenza vaccine and, 264-265, 407, 408
N meningitidis vaccine and, 265-266, 444
swine flu vaccine and, 82, 83
H1N1, H3N2, H5N1. See Influenza, strains of.
Haemophilus influenzae type b (Hib), 341-346. See also Influenza.
clinical features, 341
societal burden from, 70
correlates of protection, 37, 38t
epidemiology and transmission, 341-342
immunization program, 252, 342, 343
pathogen, 341, 572t
vaccines, 342, 344t-345t
administration errors and remedies, 171t
characteristics and specifics of, 344t-345t
combination vaccines
Pentacel (DTaP-IPV/Hib), 122t, 544t-550t
Vaxelis (DTaP-IPV-Hib-HepB), 122t, 544t-550t
immunogenicity/efficacy, 342-343
minimum ages and intervals, 156t
optimizing immunity with, 189, 196, 197
recommendations, 343-346, 344t
safety, 343, 542
reportable events, 108t
schedule, 343, 345t
adults, by age, 297
adults, by medical condition/indication, 299
children, age 0-18 years, 288
catch-up, children age 4 months-6 years, 290
storage, 122t-123t
trade names, 344t-345t
ActHIB (Hib-T), 342, 344t-345t
Hiberix (Hib-T), 342-343, 344t-345t
PedvaxHIB (Hib-OMP), 342, 344t-345t
Hajj, 225
Handling, storage, and transport of vaccines, 119-129
administration of vaccines, 120-121
during emergencies, 128t
Immunization Tsar/Tsarina, 119, 120t, 134
inventory, 119-120
keeping VFC vaccines separate, 120
signs, 119, 127
storage of vaccines, 121-127, 122t-126t
correct temperature for, 127
transportation of vaccines, 127-129
Harm. See Public harm.
HAV. See Hepatitis A.
Havrix (HepA), 123t, 349, 350t-352t
HBIG. See Hepatitis B immune globulin (HBIG).
HBV. See Hepatitis B.
Health care personnel, 94-96, 214-218
adverse event reporting by, 96
continuing education for, 95
definition of, 214-215
immunization standards for, 94-96
needlestick injuries/blood exposure/precautions, 105-111, 360
rationale for immunization, 215
sharps use and precautions, 110-111
universal precautions, 110
vaccination recommendations, 96, 114-115, 215-218, 298-299
hepatitis A, 355
hepatitis B, 111, 215-216, 360, 368
influenza, 114-115, 216, 399, 410
MMR, 216-217, 423
polio, 453
smallpox, 489-492
Tdap, 217, 325
varicella (VAR), 217-218, 513, 518
VariZIG, 218
vaccine coverage rates, 190t
Health care providers
addressing concerns about vaccines, 235-242, 238t-239t
as trusted source of information, 238, 240, 246
Health Resources and Services Administration, 558t
Healthcare Effectiveness Data and Information Set (HEDIS), 77-78, 561t
Healthy People 2020, 93
Heart disease, 294t, 298-299
Hemagglutinin, 36, 213
Hematopoietic stem cell transplantation (HSCT), 202-203, 369
revaccination recommendations, 204t-207t, 346
Hemodialysis, 294t, 298-299
hepatitis B, 368, 369
HepaGam B, 361
Hepatitis A, 347-358
in Butte County, California, 43, 349
clinical features, 347
correlates of protection, 38t
Hepatitis A, continued
epidemiology and transmission, 347-348
herd immunity and, 43
immune globulin, 356t
immunization program, 48, 348-349
pathogen, 347, 572t
vaccines, 349, 350t-352t
administration errors and remedies, 155, 171t
characteristics and specifics of, 350t-352t
combination vaccine: Twinrix (HepA-HepB), 123t, 552t-555t
contraindications/precautions, 353
immunogenicity/efficacy, 349-353
minimum ages and intervals, 19, 155, 156t, 162, 288
recommendations, 348-349, 353-355
correctional facilities, 348, 355
food handlers, 226t, 355
morticians, 227t
postexposure prophylaxis, 354-355, 356t-357t
pre-exposure prophylaxis, 222t, 353-355	ravel, 221, 348, 353
safety, 353
reportable events, 108t
schedule, 351t
adults, by age, 296
adults, by medical condition/indication, 298
children, age 0-18 years, 288
catch-up, children age 4 months-6 years, 291
catch-up, children age 7-18 years, 292
seroconversion rates, 349
storage, 123t
trade names (Havrix, Twinrix, Vaqta), 350t, 552t
Hepatitis B, 359-376
clinical features, 359-360
correlates of protection, 38t, 40
epidemiology and transmission, 360
chronic carriers, 359, 360
HBsAg (hepatitis B surface antigen), 17, 40, 359
HBsAg/HBsAb status and, 361, 367, 370t-376t
testing for, 175, 185, 215, 368-369
immune globulin (HBIG), 19, 167t, 361, 366, 370t-371t
immunization program, 360-361, 366
pathogen, 359, 572t
vaccines, 361, 362t-365t
administration errors and remedies, 171t
characteristics and specifics of, 362t-365t, 572t
combination vaccines
Pediarix (DTaP-HepB-IPV), 64t, 544t-550t
Twinrix (HepA-HepB), 123t, 552t-555t
Vaxelis (DTaP-IPV-Hib-HepB), 122t, 544t-550t
contraindications and precautions, 367
HepB-CpG (Heplisav-B), 361, 362t, 366
immunogenicity/efficacy, 361-366
The Vaccine Handbook, 9th ed.

Hepatitis B, continued
interchangeability of brands, 367
minimum ages and intervals, 156t, 288
no minimum age for, 162
purified subunits, 17
recommendations, 360-361, 367-369
adult vaccination, 367-369
correctional facilities, 360, 368
health care personnel, 215-216, 360, 368
HIV-infection, 189, 368, 369
infants/newborns, 212, 360, 367, 370t-372t
postexposure prophylaxis, 167t, 361, 369, 370t-372t, 374t-376t
preterm/low birth weight infants, 212
standing orders for high-risk individuals, 368
travel, 221, 368
universal infant, child and adolescent immunization, 367
safety, 366-367
MS, 266
reportable events, 107t
schedule, 364t
adults, by age, 296
children, age 0-18 years, 288
catch-up, children age 4 months-6 years, 290
catch-up, children age 7-18 years, 292
storage, 123t
trade names (Engerix-B, Recombivax HB, Heplisav-B), 362t
Hepatitis B immune globulin (HBIG), 19, 361, 366, 370t-371t
contraindications/precautions, 367
interval for live vaccines and, 167t
recommendations, 361, 366, 370t-371t
trade names (Nabi-HB, HepaGam B, HyperHEP B S/D), 361
Hepatitis B surface antigen. See under Hepatitis B.
Hepatitis B vaccine. See PedvaxHIB, Hib-OMP.
Hib. See Haemophilus influenzae type b.
Hib-OMP. See PedvaxHIB.
Hib-T. See ActHIB; Hiberix.
Hiberix (Hib-T), 64t, 123t, 171t, 189, 342-343, 344t-345t, 346
HIV (human immunodeficiency virus) infection, 185-189
adults, 189
AIDS, origin of, 268-269
HIV (human immunodeficiency virus) infection, continued
children/adolescents, 182, 185-189
infants, 185
postexposure prophylaxis, 111
vaccination recommendations, 185-189, 294t, 298-299
close contacts, 183
contraindications/precautions, 185, 189
H influenzae type b (Hib), 189, 343
hepatitis A, 189
hepatitis B, 189, 368
influenza, 185, 189
MMR and VAR, 182, 185-189
N meningitidis, 189, 192, 446t
pneumonia, 186-188, 189
HLAs (human leukocyte antigens), 24, 45
Homeless people, 295t, 354, 355
Hospital workers, 114-115. See also Health care personnel.
HPV. See Human papillomavirus (HPV).
HPV2, HPV4, HPV9. See Human papillomavirus (HPV) vaccines.
Human cell lines, 261, 271
Human immunodeficiency virus. See HIV.
Human leukocyte antigens (HLAs), 24, 45
Human nature, 231-235, 233
Human papillomavirus (HPV), 377-392
cancers and, 377-379, 379
clinical features, 377-378
epidemiology and transmission, 378-379
immunization program, 380-382, 381
in Australia, 383
pathogen, 377, 572t
vaccines, 382, 384t-385t
administration errors and remedies, 171t
characteristics and specifics of, 382, 384t-385t, 572t
communicating about, 388, 389t-390t
contraindications/precautions, 386
cost effectiveness, 380
coverage rates in adolescents, 387
HPV2 (Cervarix), 380, 381
HPV4 (Gardasil), 380-386, 381
HPV9 (Gardasil 9), 380-388, 381, 384t-385t
recommendations, 380, 381, 387-388
safety, 385-386
schedule, 380, 381, 384t-385t
adults, by medical condition/indication, 298
children, age 0-18 years, 288
catch-up, children 7-18 years, 292
young adult, by age group, 288
storage, 123t
immunogenicity/efficacy, 382-383
minimum ages and intervals, 157t, 288, 384t-385t
recommendations, 164, 380, 381, 387-388
adolescents, 288, 292, 381, 387-388
Herpes zoster. See Zoster (herpes zoster; shingles).
Human papillomavirus (HPV), continued
safety, 260, 383-386
autoimmune diseases, 386
Guillain-Barré syndrome, 266, 386
MS, 267
primary ovarian insufficiency, 276
reportable events, 109t
venous thromboembolic events (VTEs), 386
schedule, 381, 384t-385t
storage, 123t
Human rabies immune globulin (HRIG), 167t, 457-461, 468t-469t
Hygiene hypothesis, 258
HyperHEP B S/D, 361
Hyperimmune globulin, 19, 167t, 196
HyperRAB S/D (rabies immune globulin), 457-461
Hypersensitivity, delayed-type, 176
HyperTET S/D, 326
Hyporesponsiveness, 22
Hysteria, mass or epidemic, 275-276
ICD codes, 148, 150t-151t
IgA, IgG, IgM. See Immune globulin.
IGIM (intramuscular immune globulin)
  intervals for live vaccines and, 166t
  for measles, 430
IIIV (inactivated influenza vaccine). See Influenza, vaccines, IIV.
Illegal drug users, 226t, 295t, 353, 354, 368
Illusory truth effect, 239
Immigrants, 218-219
Immune deficiency states, 183-203. See also Impaired immunity; Special circumstances.
Immune globulin, 18-19, 166t. See also Antibodies.
  botulism (BabyBig), 167t
  deficiencies, 189-196, 335, 367, 517
  hepatitis A, 166t, 356t
  hepatitis B (HBIG), 19, 167t, 361, 366, 370t-371t
  IgA, 20, 23, 367, 462
  IgG, 18-19, 20, 23, 30
  IgM, 20, 22, 23, 30, 196
  impaired immunity states and, 183
  intramuscular (IGIM), 166t, 430
  intravenous (IGIV), 165, 166t, 183, 209
  isotypes, 19-20
    isotype switching, 26
    polyclonal, 18
  rabies (HRIG), 457-461
  time course of responses, 30
  vaccinia, 489
  varicella (VariZIG), 19, 167t, 513, 518-520
Immune memory, 23, 26-27, 27, 30-31
Immune overload, 253-254

Immune response, 19-36
  adaptive immune system, 19, 20, 27
  anamnestic response, 23, 26, 27, 31
  antibodies, 19-32
    extrafollicular reaction, 22-24, 23
    germinal center reaction, 23, 24-32
    persistence of, 30-31
    cytotoxic T cells, 32-36, 34
  genetics and, 45-46
    germinal center reaction, 23, 24-32
    homotypic vs heterotypic, 27-30
  innate immune system, 24-32, 27
    stimulating, 26, 27, 30
  live vs inactivated vaccines, 14t, 35-36
  priming and boosting, 26-27, 30, 31
    time course of, 26-27, 30
Immune thrombocytopenia (ITP), 235, 272-273, 426, 427
Immunity
  correlates of protection, 36-41, 38t-39t
  impaired. See Impaired immunity
  natural vs vaccine-induced, 253
  as presumed from vaccination, 175
testing for, 175
waning, 31, 48, 253, 327, 513
Immunization, 11-19
  active, 11
  barriers to, adolescents, 96-97
  booster, 26-27, 30, 31
  correlates of protection, 36-41, 38t-39t
definition of, 11
  ethical and moral arguments for, 113-114, 234, 242-246
general recommendations, 153-180
  herd immunity, 41-45, 41
  mandates and legislation regarding, 111-115, 410
  passive, 11, 18-19, 165, 208
  primary, 26-27, 30
  reactions to. See Adverse events.
schedules. See Schedules for immunization.
  standards. See Standards, principles, and regulations.
Immunization Action Coalition (IAC), 560t
Immunization coalitions, 134
Immunization Information Systems (IISs), 133-134
Immunization platforms, 285-286, 300t
Immunization practices, standards and guidelines for, 93-180
Immunization programs, 46-50. See also specific vaccines.
  childhood, impact of, 34, 50, 52t
  control/elimination/eradication/extinction of disease, 46-48, 49t, 253
goals of, 46-48, 93
  impact of, 48-50, 49t, 52t
  triumphs of, 49t
Immunization Safety Review Committee (ISRC), 83
Immunization Tsar or Tsarina, 119, 120t, 134
Immunocompromised states. See Impaired immunity.
Immunogenicity, 31-32, 36. See also Immune response; specific vaccines.
efficacy and, 36
immunogenicity bridging, 56
live vaccines, 26
Immunoglobulins. See Immune globulin.
Immunology, basic, 19-36. See also Immune response.
Immunosuppression. See Impaired immunity.
Immunosuppressive medications, 190t, 198-199
steroids, 198
Imogam Rabies-HT (rabies immune globulin), 457-461, 468t-469t
Imovax Rabies (RAB-HDC), 458t-460t
Impact of vaccines, 46-50, 49t, 52t
factors in determining, 58
Impaired immunity, 181-183
general considerations, 181-183
close contacts, immunization of, 183, 408
differences in immunocompromised states, 181-182
official recommendations vs package insert, 183
risks vs benefits, 181
suboptimal immune responses, 182-183
guidelines for vaccination, 185-203
immune deficiency states, 185-203, 294t
asplenia, 197-198, 294t
B-cell (humoral) deficiencies, 189-196
cancer chemotherapy, 199-200
complement deficiencies, 182, 197
disease-modifying antirheumatic drugs (DMARDs), 198-199
hematopoietic stem cell transplantation, 202-203, 204t-207t
HIV infection, 185-189, 294t
phagocyte disorders, 181-182, 196-197
solid organ transplantation, 190t, 200-202, 201
steroids, 198
T-cell deficiencies, 196
live vaccine use in households of, 165-169
newborns, 184, 203
optimizing immunity
to H influenzae type b, 189, 196, 197, 199-200
to N meningitidis, 189, 192, 197
to S pneumoniae, 184, 187, 196, 197, 199, 202
other predisposing conditions, 183-184, 203-225
passive immunoprophylaxis for, 183
vaccine coverage rates, 184, 190r-191t
vaccine recommendations, 183-203, 294t, 298-299, 355, 356t, 369
general considerations, 181-183
N meningitidis, 436
pneumococcal vaccines, 186-188
Inactivated vaccines, continued
maternal antibodies and, 19
purified subunits, 12t, 17
timing of administration, 155
vs live vaccines, 12t, 14t-15t, 35
whole agent, 12t, 17
Inborn errors of metabolism, 212-213
Indications, 68t-69t
labeled indications, 59, 64t-65t
vs official recommendations, 62, 64t-65t, 68t-69t
Infanrix (DTaP), 327, 328t-330t
cost, 148
storage, 122t
Infants, 212, 258. See also Children; Newborns.
birth vaccinations, 212, 288, 360, 366, 543
botulism immune globulin (BabyBig), 167t
cocooning strategy, 131, 324
hepatitis B vaccination, 212, 360, 366, 367, 370t-372t
HBsAg/HBsAb testing, 369
post-exposure prophylaxis, 369, 370t-372t
Hib vaccination, 164, 343
HIV and, 185
infant-toddler immunization platform, 300t
influenza vaccination, 396-399, 398, 409
maternal antibody protection, 18, 203-208
MMR, 430
neonatal varicella, 512
newborns, 184, 203, 212
pain relief for, 145
pertussis immunization, 325
pertussis in, 131, 203-208
pneumonia vaccination, 494, 495, 496-497
preterm and low birth weight, 212, 479
rotavirus vaccination, 165, 185, 212, 479
routine immunization schedule, 288
susceptibility gap, 205
varicella/VariZIG, 518, 520
Infectious Diseases Society of America (IDSA), 97, 114, 181, 559t
Inflammatory bowel disease (IBD), 260
Inflammatory reaction, 24
Influenza, 393-412
clinical features, 394-395
correlates of protection, 38t
deaths from, 395-396, 396
economic burden of, 395, 397
edemics/pandemics, 62, 393-394
A(H1N1, 2009), 62, 265, 394
H2N2 (1957, 1968), 394
preparedness for, 62
Spanish flu (1918), 383-384
epidemiology and transmission, 395-396
annual mortality, 395-396, 396
Influenza, continued

swine flu, 82, 83, 394
immunization program, 396-399, 398
cost-effectiveness of, 399
school-located vaccination, 132
pathogen, 393-394, 572t
antigenic drift and shift, 393
avian influenza viruses, 383-384
reassortment and, 393, 403
strains, 393-394
A, H, N, B molecules, 393-394
A(H1N1), 264-265, 393-394, 396, 406
   New Jersey (1976, Fort Dix), 264
   Spanish flu (1918), 393-394
   special surveillance efforts, 82
A(H3N2), 393, 394, 399, 405
A(H5N1), 403
vaccines, 399-403, 400t-402t
administration errors and remedies, 171t-172t
annual production of, 403
   2019-2020 season, 400t-402t
characteristics and specifics of, 400t-402t, 572t
effectiveness, 404-406
egg-free (Flublok, Flucelvax), 400t, 403
4-valent vaccines, 399
IIV (inactivated), 64t, 400t-401t, 403
   A (H5N1) vaccine (stockpiled), 403
   administration errors and remedies, 171t
   contraindications/precautions, 407
egg-free vaccines (Flublok, Flucelvax), 400t, 403
Fluad, 400t, 403
high-dose (Fluzone High-Dose), 213-214, 399, 401t
immunogenicity/efficacy, 404-405
jet injector for, 145
safety, 406-407
storage, 123t
immunogenicity/efficacy, 213-214, 404-406
in children, 399
LAIV (live-attenuated), 400t, 403
   administration errors and remedies, 172t
   contraindications/precautions, 165, 189, 408-409
   immunogenicity/efficacy, 405-406
   intranasal administration of, 141, 144
   reassortment backbone, 403
   safety, 407-409
   storage, 123t
recommendations, 296, 396-399, 398, 409-410
   adults, 296, 396-399, 398, 409-410
   adults over 65 years, 213-214, 296, 396, 398, 409
   annual vaccination, 399, 409
   children, 396-399, 398, 409
   children on aspirin therapy, 408, 410

Influenza, continued

during pregnancy, 203, 210t, 410
health care personnel, 114-115, 216, 399, 410
minimum ages and intervals, 157t, 288
never too late in the season, 409
priorities/high-risk patients, 409-410
travel, 221
universal vaccination, 398, 409
safety, 406-409
   Bell's palsy, 273
egg allergy and, 407
Guillain-Barré syndrome, 264-265, 407, 408
MS, 266-267
narcolepsy, 273-274
reportable events, 109t
schedule, 409
   adults, by age, 296
   adults, by medical condition or indication, 298
   children, age 0-18 years, 288
shortages of, 89
storage of, 123t
swine flu vaccine (1976), 82, 83
trade names, 400t-402t
   Afluria, 400t
   Arepanrix, 274
   Fluarix, 400t
   Flublok, 400t
   Flucelvax, 400t, 403
   Flulaval, 400t
   Flumist, 123t, 400t
   Fluzone, 401t
   Fluzone High-Dose, 213-214, 401t
   Pandemrix, 273-274
Injury. See National Childhood Vaccine Injury Act; Vaccine Injury Compensation Program.
Innate immunity, 24-32, 27
   adjuvants and, 26, 27
   stimulating, 26, 27, 30
Institute for Safe Medication Practices, 169
Institute for Vaccine Safety, Johns Hopkins, 560t
Institute of Medicine (IOM), 83
Interferon-gamma release assay (IGRA), 427, 489, 517, 528
International adoptees, refugees, and immigrants, 218-219, 348, 353
Internet resources, 558t-561t
Intervals for vaccinations, 153-162, 156t-161t
   doses in a series, 14t, 155, 163
   doses of same vaccine, 14t, 155-162
   grace period, 112, 154, 155, 162
   inactivated vaccines, 155
   lapse in series and, 163
   live vaccines, 154
Intervals for vaccinations, continued
between live vaccines and antibody-containing blood products, 164-165, 166t-168t
minimum intervals and ages, 19, 153-162, 156t-161t
simultaneous administration, 153-154
Intramuscular administration, 141-145, 142
advantages of, 26
Intramuscular administration of vaccines, 141-145, 142
Intradermal administration, 141-145, 142
advantages of, 26
Intussusception, 235, 272, 478
Inventory of vaccines, 119-120
keeping VFC vaccines separate, 120
rotation of stock, 120
IPOL (IPV), 123t, 452t-453t. See also Polio, vaccines.
IVPV. See Polio, vaccines.
IQIP (Immunization Quality Improvement for Providers), 134
Isotypes, 19-20
switching, 24, 26
ISRC (Immunization Safety Review Committee), 83
Ixiaro (JEV-VC), 123t, 415, 416t
Japanese encephalitis, 413-418
clinical features, 413
correlates of protection, 38t
epidemiology and transmission, 224, 414
immunization program, 414-415
pathogen, 413, 572t
vaccines, 415, 416t
contraindications/precautions, 417
immunogenicity/efficacy, 415
JEV-MB, 414-415
JEV-VC (Ixiaro), 415, 416t
recommendations, 417
laboratory workers, 417
table, 224, 417
schedule, 416t
storage, 123t
trade name: Ixiaro (JEV-VC), 416t
Jenner, Edward, 16
JEV. See Japanese encephalitis.
Jynneos, 126t, 483-489, 486t-487t
safety, 483, 488
Kawasaki disease, 166t, 270
Kidney failure/disease, 184, 294t, 298-299, 368
Kinrix (DTaP-IPV), 122t, 173t, 544t-550t
Labeled indications, 59, 68t-69t
vs official recommendations, 62, 64t-65t
Laboratory workers, vaccination of, 111, 226t, 312, 354, 417, 445,
446t, 453, 464t, 482, 489, 509
LAIIV (live-attenuated influenza vaccine). See Influenza, vaccines, LAIV.
Measles, Mumps, Rubella, continued

elimination/eradication of, 47, 49t, 423
resurgence of, 48, 248-252, 422-426
measles, 248-252, 251, 422-423, 425
mumps, 48, 422, 425-426
rubella
congenital rubella syndrome (CRS), 421, 426
declared eliminated from the Americas, 426
proof of immunity, 208, 428, 428t-429t
vaccines (MMR), 12t, 422-423, 424t-425t
characteristics and specifics of, 424t-425t
combination vaccine (MMRV), 422, 541, 543, 552t-555t.
See also MMRV vaccine.
vs MMR plus VAR, 422, 541, 543
contraindications/precautions, 427
evidence/proof of immunity, 208, 428t-429t
immunogenicity/efficacy, 421-426
interval for receipt of antibody-containing products, 164-165, 166t-168t
licensing, 422
recommendations, 64t-65t, 422-423, 430
health care personnel, 216-217, 423
HIV-infected individuals, 182, 185-189
postexposure prophylaxis (measles), 430
safety, 235, 271, 426-427
autism concerns, 261-262
febrile seizures, 271, 422, 426
ITP, 235, 272-273, 426
reportable events, 106t-107t
schedule, 422, 424t-425t
adults, by age, 296
adults, by medical condition/indication, 298
children, age 0-18 years, 288
catch-up, children age 4 months-6 years, 291
catch-up, children age 7-18 years, 292
minimum ages and intervals, 158t, 288
storage, 124t
trade name (M-M-R$_{II}$), 424t
Medicaid, 88, 558t
Medical home, 130-132
Medicare, 88, 558t
Membrane attack complex, 20, 21
Memory B-cells, 23, 26, 27, 30-31
Memory T and Th-cells, 26, 27
Men who have sex with men, 226t, 295t, 298-299, 353, 368
Menactra (MenACWY-D), 40, 172t, 434, 436, 437, 438t-441t
imunogenicity, 442
minimum ages and intervals, 158t
recommendations, 299, 434, 436, 445, 446t
safety, 444
schedules, 192-195, 288, 292, 440t
storage, 124t
MenB, 173t, 436
recommendations, 445, 446t
schedules, 192-195, 289, 297, 299
use of same product in series, 163-164, 445
MenB-4C (Bexsero), 173t, 435-437, 438t-441t
adjuvant, 28t
immunogenicity, 442, 443
minimum ages and intervals, 157t
recommendations, 64t, 436, 437
schedules, 173t, 291, 440t
storage, 124t
MenB-FHbp (Trumenba), 173t, 435, 437-442, 438t-441t
immunogenicity, 442
minimum ages and intervals, 158t
recommendations, 64t, 437, 445
safety, 444
schedules, 173t, 440t
storage, 124t
Meningitis, 433-435. See also Neisseria meningitidis.
aseptic, 413, 419, 421
with polio, 449
Haemophilus influenzae type b and, 341
invasive meningococcal disease (IMD), 225, 434
meningococcal, 433-434
mumps and, 419, 421
pneumonia and, 493, 494, 497
Meningococcal vaccines. See Neisseria meningitidis.
Menveo (MenACWY-CRM), 172t, 435-437, 438t-441t
Bell's palsy and, 273
immunogenicity, 442-443
recommendations, 64t, 440t
safety, 444
storage, 124t
Mercury (thimerosol) in vaccines, 262-263
Methotrexate, 198-199
MF59 (adjuvant), 29t, 256, 403
MHC, MHC-I, MHC-II. See Major histocompatibility complex.
Military personnel, 227t
adenovirus vaccination, 305
anthrax vaccination, 309, 311, 312
N meningitidis, 445, 446t
smallpox vaccination, 482, 488
Mill, John Stuart, 113-114
Minimum age and intervals for vaccination, 19, 153-163, 156t-161t, 288
doses of same vaccine, 155-162
intervals for receipt of antibody-containing products, 164-165, 166t-168t
rule: all vaccines have a minimum age, 162-163
Miscarriage, 274-275
Missed opportunities, 130, 177
MMR vaccine. See Measles, Mumps, Rubella.
MMRV vaccine (ProQuad), 422, 541, 552t-555t. See also Measles, Mumps, Rubella.
administration errors and remedies, 173t
contraindications and precautions, 543
febrile seizures and, 271, 542, 543
interval for receipt of antibody-containing products, 165, 166t-168t
recommendations/preference for, 543
storage, 125t
vs MMR plus VAR, 422, 541, 543

Monitoring
adverse events. See Adverse events.

vaccine delivery and coverage, 73-78, 76, 129-135
vaccine safety, 78-83

Moral intuition vs reasoning, 234. See also Ethics.

Morbidity and mortality. See Deaths.

Morbidity and Mortality Weekly Report, 67

MPSV4, 435, 436, 442

Mucosal surfaces, 20, 154, 165

Multiple sclerosis, 266-267

Multiple vaccines, simultaneous administration of, 64t, 95, 136, 153-155.
See also Combination vaccines.

exceptions, 153

immune overload concept, 253-254

Mumps. See Measles, Mumps, Rubella.

Mycobacterium bovis, 16

Nabi-HB, 361

Narcolepsy, 273-274

National Adult Immunization Plan, 97

National Center for Immunization and Respiratory Diseases (NCIRD), 63, 66, 78

National Childhood Vaccine Injury Act, 79, 83, 99-105

National Coalition for Adult Immunization, 97

National Drug Codes (NDCs), 147

National Foundation for Infectious Diseases, 560t

National Health Interview Survey (NHIS), 77, 561t

National Immunization Survey (NIS), 73-77, 561t

National Institute of Allergy and Infectious Diseases (NIAID), 558t

National Institutes of Health (NIH), 55, 66

National Meningitis Association, 560t

National Notifiable Disease Surveillance System (NNDSS), 78, 561t

National Respiratory and Enteric Surveillance System (NREVSS), 78

National Vaccine Advisory Committee (NVAC), 66, 72, 93, 558t

adult immunization standards, 97, 98t-99t

immunization registries, 133

pediatric immunization standards, 93-97

National Vaccine Error Reporting Program (VERP), 169

National Vaccine Injury Compensation Program, 99-101. See also Vaccine Injury Compensation Program (VICP).

National Vaccine Plan, 73

National Vaccine Program Office (NVPO), 66, 72, 558t

Native Americans and Alaska Natives, 227t, 343

Natural infection, vs immunization, 253

Natural killer cells, 20

Necessity of vaccines, 252-253

Needle type and length, 141, 142, 143t

Needlestick injuries, 105, 360, 374t

Neighborhood, immunization, 130-132

Neisseria meningitidis, 433-438

clinical features, 433-434
correlates of protection, 38t
epidemiology and transmission, 434-435
eroserogroups, 434-435, 437, 438t, 442-443

immunization program, 434, 435-437, 436
cost-benefit, 435, 437

pathogen, 433, 572t

vaccines, 437-442, 438t-441t
adjuvants, 28t, 439t
administration errors and remedies, 172t-173t
characteristics and specifics of, 438t-441t, 572t
combination vaccine: Vaxelis (DTaP-IPV-Hib-HepB), 122t, 544t-550t
contraindications/precautions, 153, 444
immunogenicity/efficacy, 442-443
licensure of, 40, 435, 442

MenACWY, 12t, 192-195, 434, 435-437, 436

recommendations, 445, 446t

MenACWY-CRM, 40, 435-437, 438t-441t
Bell’s palsy and, 273
development cost, 53
immunogenicity, 442-443
safety, 444

MenACWY-D, 40, 435, 436, 438t-441t

immunogenicity, 442
MenB, 12t, 192-195, 436

recommendations, 445, 446t

MenB-4C, 438t-441t, 442, 443

MenB-FHbp, 437-442, 438t-441t

recommendations, 64t, 445

safety, 444

minimum ages and intervals, 157t-158t, 291

MPSV4, 435, 436, 442

reportable events, 109t
optimizing immunity with, 192-195

recommendations, 64t, 435-437, 436, 444-445, 446t
adolescents, 291, 435, 436, 444-445, 446t
college students, 435, 436, 437, 445, 446t
during pregnancy, 210t
travel, 225, 445, 446t
universal adolescent immunization, 434, 436, 444-445
use of same product in series, 163-164, 445

safety, 444

Bell’s palsy, 273
Neisseria meningitidis, continued

- Guillain-Barré syndrome, 265-266, 444
- reportable events, 109t
- schedule, 440t, 444-445
- adults, by age, 296-297
- adults, by medical condition/indication, 299
- children, age 0-18 years, 288-289
- catch-up, children age 7-18 years, 292
- storage, 124t

trade names, 438t
- Bexsero (MenB-4C), 438t
- Menactra (MenACWY-D), 437, 438t
- Menveo (MenACWY-CRM), 437, 438t
- Trumenba (MenB-FHbp), 437, 438t
- Vaxelis (DTaP-IPV-Hib-HepB), 544t

Nephrotic syndrome, 184

Neutralization of pathogens, 20, 21

New Vaccine Surveillance Network (NVSN), 78

Newborns, 18, 184, 212. See also Infants.
- hepatitis B vaccination, 212, 360
- neonatal tetanus, 322, 323
- vaccinations given at birth, 212, 288, 360, 366, 543

Nomenclature, vi-vii, 572-573t

Noninferiority, 56, 542

Number
- of antigens, in combination vaccines, 542, 543
- of antigens, in routine vaccines, 254, 255t, 258
- folk numeracy, 234
- human nature/understanding of, 231-235, 233
- of subjects, in clinical trials, 55-56, 56, 57t

Nursing homes, coverage survey, 77

Obiltoxaximab, 309, 312

Occupational Safety and Health Administration (OSHA), 105-111

Office visit, coding and billing example, 148, 150t-151t

Offit, Paul, vi, 562

Older adults, 213-214, 296-297
- immunization coverage rates, 190t
- immunization platform, 300t
- immunization schedule, 296-297
- influenza immunization, 213-214, 296, 396, 398
- life-course immunization, 213
- pneumonia immunization, 214, 495, 496, 501
- zoster vaccination, 214, 539

Opsonization, 20, 21

OPV. See Polio, vaccines.

Oral administration of vaccines, 141, 144

OSHA (Occupational Safety and Health Administration), 105-111

Otitis media, 493, 497

Overimmunization, 543

Package insert (PI), 59-62, 154, 183
- labeled indications, 59, 64t-65t

Pain (of administration), dealing with, 145

Palivizumab (Synagis), 19, 165, 168t

PAMPs (pathogen-specific molecular patterns), 24, 26

Pan American Health Organization, 558t

Pandemics
- compensation for vaccination injuries due to, 489
- legal immunity for manufacturers of pandemic vaccines, 105
- preparedness for, 62, 105

Pandemrix, 273-274

Parents of Kids With Infectious Diseases, 560t

Passive immunization, 11, 18-19, 165, 183
- during pregnancy, 18, 208
- potential inactivation of live vaccines, 19

Pasteur, Louis, 16, 17

Pathogens, 572t-573t. See also pathogen subentry under specific agents
- antibody effects on, 19-21, 20
- pathogen-specific molecular patterns (PAMPs), 24, 26
- reservoirs for, 42, 46

Patient Protection and Affordable Care Act (ACA), 84

Patternicity, 234


Pediarix (DTaP-HepB-IPV), 64t, 122t, 544t-550t
- adjuvant, 256
- safety, 542

Pediatric immunization standards, 93-97. See also Children; Infants.

Pediatric Infectious Diseases Society, iv, 114, 559t

PedvaxHIB (Hib-OMP), 123t, 342, 343, 344t-345t
- adjuvant, 28t, 256

Pentacel (DTaP-IPV/Hib), 122t, 171t, 542, 544t-550t

Personal belief exemptions, 113

Pertussis, 321-339. See also Diphtheria, tetanus, and pertussis
- clinical features, 322-323
- correlates of protection, 40
- epidemiology and transmission, 323-324
- maternal immunization and, 203-208, 331
- immunization program, 324-326, 325
- pathogen, 321-322, 572t
- pertussis toxin (PT), 321-322
- resurgence of, 48, 248, 263, 327
- vaccines, 326, 328t-330t, 572t
- acellular, 326-327
- combination vaccines, 542-543, 544t-550t
- contraindications/precautions, 331-335
- immunogenicity/efficacy, 326-331
- recommendations, 324-326, 325, 335-336
- adult. See Tdap vaccines.
- children/infants. See DTaP vaccines.
- pregnant women, 131, 331
- safety, 331-335
The Vaccine Handbook, 9th ed.

Index

Pertussis, continued
  allergies and, 259, 331
  brain damage concerns, 263-264
  encephalopathy, 176, 263-264, 331
  reportable events, 106t
  schedule, 329t, 335-336
  trade names, 328t, 544t
  Adacel (Tdap), 328t-330t
  Boostrix (Tdap), 328t-330t
  Daptacel (DTaP), 328t-330t
  Infanrix (DTaP), 328t-330t
  whole-cell, 17, 264
  waning immunity and, 48, 253, 327
Phagocyte disorders, 181-182, 196-197
Phagocytes/phagocytosis, 20, 21
Pharmacists
  American Pharmacists Association, 559t
  vaccine administration by, 131
Phase 1, 2, 3, and 4 trials, 55-58, 56
“Pink Book” (Epidemiology and Prevention of Vaccine-Preventable Diseases), 67
Placebo, 56
Plasma cells, 20, 22, 23, 30-31
  longevity of, 31
Pneumococcal vaccines, 493-502, 498t-499t
  characteristics and specifics of, 496, 498t-499t, 573t
  contraindications/precautions, 164, 501
  correlates of protection, 39t
  immunization program, 494-496, 495
  cost-effectiveness of, 496
  herd immunity and, 43, 44, 45, 496
  impact of, 43, 44, 45
  immunogenicity/efficacy, 496-500
    CAPITA study, 214, 497
    minimum ages and intervals, 158t, 186-188, 288
    optimizing immunity with, 186-188
    PCV7, 494, 495, 497
    serotype replacement, 43, 45, 50, 494
    PCV13 (Prevnar 13), 494-501, 495, 498t-499t
    administration errors and remedies, 173t
    immunogenicity/efficacy, 497-500
    minimum age and intervals, 158t, 186-188, 288
    optimizing immunity with, 186-188
    safety, 500
    schedule, 499t, 501
      adults, by age, 296
      adults, by medical condition/indication, 298
      children, age 0-18 years, 288
      catch-up, children, age 4 months-6 years, 291
    storage, 124t
    PPSV23 (Pneumovax 23), 495, 496, 497-501, 498t-499t
      23-valence, 496
      administration errors and remedies, 173t
  immunogenicity/efficacy, 214, 500
  minimum age and intervals, 158t, 186-188
  optimizing immunity with, 186-188
  safety, 500-501
  schedule, 499t
    adults, by age, 296
    adults, by medical condition/indication, 298
    children, age 0-18 years, 289
  storage, 124t
  recommendations, 494-496, 495, 501
    adolescents, 495, 496
    children, 288, 289, 494-497, 501
    older adults, 214, 495, 496, 501
  replacement disease and, 494
  safety, 500-501
  reportable events, 108t
  serotype replacement, 43, 45, 50, 494
  storage, 124t
Pneumonia, 493-494. See also Pneumococcal vaccines.
  clinical features, 493-494
  invasive pneumococcal disease (IPD), 493, 494, 496-500
  epidemiology and transmission, 494
  immunization program, 494-496, 495
  impaired immunity and, 184
  mortality from, 213, 494
  optimizing immunity to, 186-188
  pathogen, 493, 573t
  serotype replacement, 43, 45, 50, 494
  Pneumovax 23 (PPSV23), 494-501, 495, 498t-499t.
  See also Pneumococcal vaccines, PPSV23.
Policy. See Vaccine policy.
Polio, 449-454
  clinical features, 449
  correlates of protection, 38t
  proof of immunity, 450
  epidemiology and transmission, 224, 449-450
  Americas certified free of, 47, 49t, 450
  countries where endemic (2019), 451
  OPV-derived polio cases, 47, 450
  immunization program, 450
  pathogen, 449, 572t
  Americas certified free of, 47, 49t, 450
  elimination/eradication of, 47, 49t, 450
  proof of immunity, 450
  vaccines, 451, 452t-453t
  characteristics and specifics of, 452t-453t
  combination vaccines, 544t-550t
    Kinrix (DTaP-IPV), 122t, 544t-550t
    Pediarix (DTaP-HepB-IPV), 64t, 544t-550t
    Pentacel (DTaP-IPV/Hib), 122t, 453, 544t-550t
    Quadracel (DTap-IPV), 544t-550t
Polio, continued

Vaxelis (DTaP-IPV-Hib-HepB), 122t, 544t-550t
immunogenicity/efficacy, 451
inactivated (IPV), 450, 452t-453t
3-valent, 453, 541
combination vaccines, 544t-550t
contraindications/precautions, 451-452
immunogenicity/efficacy, 451
minimum ages and intervals for, 157t, 288
recommendations, 453-454
safety, 451-453
schedule, 452t, 453
children, age 0-18 years, 288
catch-up, children 7-18 years, 292
catch-up, children age 4 months-6 years, 291
storage, 123t
oral (OPV), 450, 451
2- and 3-valent, 451, 453, 541
polio cases caused by, 47, 450
proof of immunity, 450
recommendations, 450, 453-454
for travel, 221-224, 450, 453
safety, 451-453
AIDS not caused by, 268-269
reportable events, 107t
SV40 and cancer, 268
Salk, Jonas, and, 17
trade name (IPOL), 123t, 452t
Polyclonal immune globulin, 18
Polymorphisms, 45-46
Polysaccharide antigens, 17-18, 22-24, 23, 31-32
hyporesponsiveness and, 22
immune response to, 22-24, 23
original polysaccharide sin, 22
protein carriers and, 31-32
Polysaccharide vaccines, 17-18, 31-32, 33t
hyporesponsiveness and, 22
protein-polysaccharide vaccines, 18, 23, 31-32
advantages of, 31-32, 33t
pure, 18
Postherpetic neuralgia (PHN), 531, 532
PPSV23. See Pneumococcal vaccines, PPSV23.
Precautions. See Contraindications and precautions.
Prefilled syringes, 121
Pregnancy, 203-209, 210t-211t
hepatitis B antigen (HBsAg), testing for, 369
as indication for vaccination, 176, 203-208, 210t, 274, 294t
passive immunization in, 18, 208
rubella, proof of immunity, 208, 428, 428t-429t
vaccination during, 203-208, 210t-211t, 294t, 298-299
birth defect concerns, 176, 203, 208, 274-275
contraindications/precautions, 165, 176, 209, 210t, 535, 539

Pregnancy, continued
indications for, 176, 203-208, 210t, 294t, 430
infection, 203, 210t, 298, 408, 410
live vaccines, 14t, 209
generally contraindicated during pregnancy, 176, 209, 210t
exceptions to, 209, 210t
for household contacts, 165-169, 209
maternal immunization platform, 203, 300t
miscarriage concerns, 274-275
MMR, 422, 427, 430
pertussis, 131
smallpox, 488, 490t
T'dap, 203-208, 210t, 298, 325, 326, 331, 336
varicella, 209, 210t, 516-517
VariZIG, 209, 518
yellow fever, 176, 209, 210t, 528, 529
vaccine coverage rates, 190t
PREP Act, 105, 489
Preservatives, 256. See also specific vaccines.
Prevention of infection, 20, 35, 36
vs prevention of disease, 35, 78
Prevnar, 124t, 494-501, 495, 498t-499t. See also Pneumococcal vaccines, PCV13.
Primary immunization, 26-27, 30
Primary ovarian insufficiency (POI), 276
Primary vaccine failure, 31, 60t-61t, 513
Priming and boosting, 26-27, 30, 31
PRISM (Post-licensure Rapid Immunization Safety Monitoring), 81
ProQuad, 125t, 552t-555t. See also MMRV vaccine (ProQuad).
Protein-polysaccharide vaccines, 18, 31-32
advantages of, 31-32, 33t
Public harm. See also Ethics
alternative schedules and, 257-258
do no harm dictum, 234
from fear and refusal of vaccines, 231, 242-246
of vaccination refusal, 242-246, 244
of vaccine hesitancy, 231
Public health, 46-50. See also Concerns about vaccines, addressing.
impact of vaccines, 46-50, 49t, 52t
Public health emergency
compensation for vaccination injuries due to, 489
polio, international spread of, 224
preparedness for, 62, 105
vaccine stockpiles for, 62, 89-90, 403
Public Readiness and Emergency Preparedness Act, 105, 489
Public safety workers, vaccination of, 227t, 368
Purified subunits, 12t, 17
Purple Book, vi
dedication to Paul Offit, vi
Purpura fulminans, 433
Index

Quadracel (D'Tap-IPV), 122t, 171t, 544t-550t
Questions about vaccines. See Concerns about vaccines.

RAB-HDC (Imovax Rabies), 124t, 458t-460t
RAB-PCEC (RabAvert), 124t, 458t-460t
RabAvert (RAB-PCEC), 124t, 458t-460t
Rabies, 455-469
clinical features, 455-456
correlates of protection, 38t
epidemiology and transmission, 224, 456
immune globulin (HRIG), 167t, 457-461, 468t-469t
immunization program, 457
pathogen, 455, 573t
vaccines, 457-461, 458t-460t
administration errors and remedies, 173t
characteristics and specifics of, 458t-460t, 573t
contraindications/precautions, 461-462
immunogenicity/efficacy, 461
interchangeability of, 462
no minimum age for, 162
postexposure prophylaxis, 65t, 457, 461, 466t-469t
with immune globulin (HRIG), 167t, 457-461, 468t-469t
regimens for, 468t-469t
wound cleansing, 468t-469t
pre-exposure vaccination (prophylaxis), 457, 461, 464t-465t
recommendations, 457, 462, 464t-467t
animal evaluation, 466t-467t
animal handlers, 111, 464t
teach, 224
travel, 466t-467t
schedule, 459t, 464t, 468t
storage, 124t
trade names (Imovax Rabies, RabAvert), 458t
wildlife, oral vaccination of, 456
Rabies immune globulin, human (HRIG), 457-461, 468t-469t
interval for live vaccines and, 167t
safety, 461-462
Rapid cycle analysis, 81
Raxibacumab, 309, 312
Reactions to vaccines. See also Adverse events.
anaphylaxis, 106t-107t, 146-147, 176
injection-site. See specific vaccines.
Reassortment, 16, 393, 403
Recall and tracking systems, 130
Recombinant DNA technology, 18
Recombinant subunit vaccines, 12t, 18
Recombivax HB (HepB), 123t, 361, 362t-365t, 367
Recommendations, vii, 62-73, 80, 153-180. See also Administration of vaccines; specific vaccines.
AAAP, 71-72
ACIP, vii, 63-71, 74t-75t, 543
administration errors and corrections, 169-175, 170t-174t

Recommendations, continued
adult immunization, 67
agencies involved with, 62-73, 66
categories and language, 74t-75t
child/adolescent schedule, 67
considerations for making, 70
contraindications and precautions, 176-177
disease burden and, 70
Evidence to Recommendations (EtR) framework, 70, 72t
General Best Practice Guidelines, 67, 177
general recommendations, 153-180
GRADE approach, 67-70, 71t
intervals for receipt of antibody-containing blood products, 164-165, 166t-168t
minimum age and intervals for vaccinations, 153-163, 156t-161t, 288
official, vs labeled indications, 62, 64t-65t, 68t-69t
routine schedules, 285-300. See also Schedules for immunization.
shared clinical decision-making (SCDM), 70-71, 74t, 388
special circumstances, 181-230
ten simple rules, 153-169
terminology in reference to, 68t-69t, 74t
vaccination of persons who have had the disease, 164, 179t, 336
vaccine handling, storage, and transport, 119-129
vs package insert, 59-62, 64t-65t, 154, 183
“when in doubt, vaccinate,” 164
Records, vaccination/medical, 95-96, 102t, 129, 218
“Red Book” (Report of the Committee on Infectious Diseases), 71
Refrigerator, storage of vaccines in, 121-127, 122t-125t
Refusal of vaccination, 242-246, 244
forms for, 245
modified schedules, 257-258
physician dismissal of vaccine-refusing families, 245-246
public harm from, 242-246
Registries (Immunization Information Systems), 133-134
Regulations. See Standards, principles, and regulations.
Religious exemptions, 113
Reminder, recall, and tracking systems, 130
Report of the Committee on Infectious Diseases (“Red Book”), 71
Reportable Events, 99-101, 106t-109t
Reporting of adverse events, 79-81, 106t-109t
mandatory reporting, 79, 96, 101, 103t
to VAERS, 79-81, 101-105, 103t, 169t
Respiratory disease, vaccinations recommended, 298-299
Respiratory syncytial virus (RSV), antibody against, 19, 165, 166t
Reverse genetics, 403
Reverse vaccinology, 18, 442
Reye syndrome, 138t, 226t, 408, 410, 517
Rheumatoid arthritis, 198
RhoGAM, 167t
Ring vaccination, 46, 482
Risks and benefits of vaccines, 78, 235
communicating about, 235-242, 238t-239t
costs of public concern, 236t, 248-252
human nature and, 231-235
risks vs benefits, balancing, 78, 181, 235, 237t
Rotarix (RV1), 124t, 473-479, 474t-476t. See also Rotavirus, vaccines.
administration, 144
RotaShield (RRV-TV), 235, 272, 472
RotaTeq (RV5), 124t, 473-479, 474t-476t. See also Rotavirus, vaccines.
administration, 144
Rotavirus, 471-480
clinical features, 471
disease burden, 70, 472
epidemiology and transmission, 472
immunization program, 235, 472-473
cost-effectiveness, 473
decline in rotavirus activity due to, 477-478, 477
pathogen, 471, 573t
vaccines, 473, 474t-476t
characteristics and specifics of, 474t-476t, 573t
contraindications/precautions, 478
development cost of, 53
heterologous host, 16
immunogenicity/efficacy, 473-478, 477
minimum ages and intervals, 19, 159t, 288
oral administration, 141, 144
reassortment and, 16
recommendations, 65t, 473, 479
infants, 185, 479
preterm infants, 212, 479
same product in a series, 479
RRV-TV, 235, 272, 472
RV-1 (Rotarix), 12t, 473-479, 474t-476t
safety, 272, 478
RV-5 (RotaTeq), 12t, 473-479, 474t-476t
development cost, 53
safety, 272, 478
safety, 236t, 237t, 478
intussusception concerns, 235, 272, 478
porcine circovirus contamination, 271
reportable events, 108t
risks vs benefits, 236t, 237t
type 1 diabetes, 259
schedule, 476t
children, age 0-18 years, 288
catch-up, children, 4 months-6 years, 290
serial passage, 16, 271
storage, 124t-125t
Routes of administration, 14t, 141-145, 142. See also Administration of vaccines.
errors in, 169-175, 170t
parenteral, 20
Routine schedules. See Schedules for immunization.
RSV. See Respiratory syncytial virus (RSV).
Rubella. See Measles, Mumps, Rubella.
Rubeola. See Measles.
Rules for vaccination, 153-169. See also Recommendations.
RZV (recombinant zoster vaccine). See Zoster.
Sabin, Albert, 11
Sabin Vaccine Institute, 560t
Safety of vaccines, 235. See also Adverse events; Vaccine Safety Net; and specific vaccines.
communicating about, 235-242, 238t-239t
meaning of safety, 235
monitoring of safety, 78-83
on-time schedules, 258
postmarketing surveillance, 78-83, 80
safety does not mean harmless, 235
side effects and, 235
Vaccine Safety Net, 78-83, 80
Salicylates. See Aspirin.
Salk, Jonas, 17
Salmonella enterica, 503
Salmonella typhi, 16, 220, 503, 573t. See also Typhoid fever.
Schedules for immunization, 285-300. See also specific vaccines.
adults, by age group, 296-297
adults, by medical indication, 298-299
children, age 0-18 years, 288-289
catch-up schedule, children age 4 months-6 years, 290-291
catch-up schedule, children age 7-18 years, 292-293
children and adolescents, routine immunizations, 288-289
children and adolescents, special immunizations, 294t-295t
flexibility within, 285
high-risk individuals. See Special circumstances
modified/alternative schedules, 155, 257-258
platforms, 285-286
safety of, 258
Schools
coverage surveys, 77
school-aged immunization platform, 300t
school immunization mandates, 112-114
school-located vaccination (SLV), 132
Screening for contraindications/precautions, 135, 138t-140t, 241
Section 317 funds, 85-88, 94
Seizures, 264, 271. See also Febrile seizures.
Self/non-self recognition, 24, 25-26
Serial passage, 11-16, 271
Seroconversion, testing for, 175
Serology, 175
Serotype replacement, 43, 45, 50, 494
Sewage workers, 227t
Shared clinical decision-making (SCDM), 70-71, 74t, 388, 437
Sharps use and precautions, 110-111
Shingles. See Zoster (herpes zoster; shingles).
Shingrix (RZV; recombinant zoster vaccine), 35, 125t, 534-539, 536t-538t. See also Zoster.
Shortages of vaccines, 89-90
deferral of doses and, 89
Sickle cell disease, 190t, 197
Side effects. See Adverse events.
SDIS (sudden infant death syndrome), 269
Simian immunodeficiency virus (SIV), 268-269
Simian virus 40 (SV40), 268
Smallpox, 481-492
bioterrorism potential of, 47, 482-483
clinical features, 481-482
diagnosis of, 481, 484t-485t
differentiating from chickenpox, 484t-485t
mortality rates, 481
correlates of protection, 38t
epidemiology and transmission, 482
immunization program, 482-483
ring vaccination, 46, 482
pathogen, 481, 573t
cross-protection from vaccinia virus, 483
elimination/eradication of, 46-47, 49t, 482
vaccines, 483-487, 486t-487t
ACAM2000, 125t, 483-489, 486t-487t
administration and handling, 141-144, 487
characteristics and specifics of, 486t-487t, 573t
compensation for injuries (pandemic/epidemic use), 489
contraindications/precautions, 153, 165, 209, 488-489, 490t-491t
Dryvax, 483, 487
immunogenicity/efficacy, 487-488
Jenner and, 16
Jynneos, 126t, 483-489, 486t-487t
post-event vaccination, 483, 489
pre-event vaccination, 482-483, 490t
recommendations, 482-483, 489-492
revaccination, 492
smallpox attack/event, 482-483, 492
safety, 483, 488-489, 490t-491t
schedule, 487t
storage, 125t-126t
Ticovirimat (antiviral smallpox treatment), 489
trade names
ACAM2000, 486t
Jynneos, 126t, 486t
vaccinia immune globulin intravenous, 489
Society of Teachers of Family Medicine, 560t
Somatic hypermutation, 25
Special circumstances, 181-230. See also Impaired immunity
adults over 65 years of age, 213-214
coverage rates in special populations, 184, 190t-191t
health care personnel, 214-218
Special circumstances, continued
immune deficiency states, 185-203
impaired immunity, 181-183, 294t
B-cell (humoral) deficiencies, 189-196
cancer chemotherapy, 199-200
disease-modifying antirheumatic drugs (DMARDs), 198-199
hematopoietic stem cell transplantation, 202-203, 204t-207t
HIV infection, 185-189, 294t
solid organ transplantation, 200-202, 201
inborn errors of metabolism, 212-213
international adoptees, refugees, and immigrants, 218-219
newborns, 184, 212
other predisposing conditions, 183-184, 203-225
other special situations, 226t-227t
pregnancy, postpartum, and breastfeeding, 203-209, 210t-211t, 294t
preterm and low birth weight infants, 212
tavel, 219-225
specificity of antibodies, 19, 27-30
Spelunkers, 227t, 464t
Standards, principles, and regulations, 93-118. See also Vaccine infrastructure; Vaccine practice.
Bloodborne Pathogens Standard, 105-111
coverage goals, 93
federal requirements regarding vaccination, 102t-104t
Healthy People 2020, 93
immunization practices, standards, 93-99
adult, 97, 98t-99t
child and adolescent, 93-97
mandates and exemptions, 111-115
National Childhood Vaccine Injury Act, 99-105
National Vaccine Injury Compensation Program (VICP), 99-101
Occupational Safety and Health Administration (OSHA), 105-111
Public Readiness and Emergency Preparedness Act, 105
Reportable Events Table, 106t-109t
reporting of adverse events, 79-81
standard of care, 69t
training, 111
Vaccine Adverse Event Reporting System (VAERS), 79-81, 101-105
Vaccine Information Statements (VISs), 102t, 105
Standing orders, 133, 368
Steroids, 198
Stockpiles of vaccines, 62, 89-90, 403
Storage of vaccines, 119-129, 122t-126t. See also specific vaccines.
emergency provisions for, 128t
in freezer, 121-127, 125t-126t
in refrigerator, 121-127, 122t-125t
temperature monitoring and logs, 121-127
Streptococcus pneumoniae, 493-502, 573t. See also Pneumococcal vaccines; Pneumonia.
impaired immunity and, 184
optimizing immunity to, 186-188
serotypes and herd immunity, 43, 44, 45
Students. See College students; Schools.
Subcutaneous administration of vaccines, 141, 142, 143t
Subunits
  engineered, 12t, 18
  purified, 12t, 17
  recombinant, 12t, 18
Sudden infant death syndrome (SIDS), 269
Supply of vaccines, 89-90
Surrogates of immunity. See Correlates of protection.
Surveillance, 78, 482-483. See also Vaccine Safety Net.
special surveillance efforts, 82
SV40 contamination of early polio vaccine, 268
Swine flu, 82, 83, 394
Synagis (palivizumab), 19, 165, 168t
Syncope, 106t-109t, 146
Systems immunology, 18

T cells, 23, 27
cytotoxic (Tc cells), 25, 32-36, 34
  activation of, 32, 34
  deficiencies of, 182, 196
helper (Th-cells), 23, 24-25, 32, 35
  memory Th-cells, 26
hygiene hypothesis and, 258
memory T-cells, 26, 27
T-cell-dependent responses, 32, 35
T-cell-independent antigens and responses, 22, 32, 33t
T-cell receptor (TCR), 23, 24, 25, 32, 34
Table injury, 100
Task Force on Safer Childhood Vaccines, 83
T'd (tetanus, diphtheria) vaccine, 332t-333t, 335
  contraindication and precautions, 334-335
  minimum ages and intervals for, 159t
  recommendations, 335-336
    for wound management, 338t-339t
  schedule, 332t, 335
  adults, by age, 296
  adults, by medical condition/indication, 298
  catch-up, children age 7-18 years, 292
  trade names
    Tenivac, 332t-333t
    Tetanus and Diphtheria Toxoids Adsorbed, 332t-333t
T'dap vaccines, 328t-330t. See also Diphtheria, tetanus, and pertussis.
  administration errors and remedies, 174t
  contraindications/precautions, 334
    Guillain-Barré syndrome, 334
    immunogenicity/efficacy, 326
    licensure of, 40, 327
  minimum ages and intervals, 159t, 288
  recommendations, 65t, 324-326, 325, 329t, 335-336
    health care personnel, 217, 325
    postpartum women, 131
    pregnancy, 203-208, 210t, 325, 326, 331, 336
    for wound management, 338t-339t
    safety, 331-335
    schedule, 329t, 335-336
    adults, by age, 296
    adults, by medical condition/indication, 298
    catch-up, children age 7-18 years, 292
    children, age 7-18 years, 288
    storage, 125t
    trade names (Adacel, Boostrix), 328t-330t
      vs DTaP, 164
    waning immunity, 48, 253, 327
    Temperature for vaccine storage, 127
    Tenivac (Td), 125t, 322t-333t. See also T'd (tetanus, diphtheria).
Terminology, vi-vii, 11, 572t-573t
  inactivated vaccines, 17
  indication, recommendation, requirement, 68t-69t
  language and meaning, 242, 243t
Terrorism
  anthrax and, 307-308, 312
  smallpox and, 47, 482-483
Tetanus, 321-339. See also Diphtheria, tetanus, and pertussis
  clinical features, 322
  correlates of protection, 39t
  epidemiology and transmission, 253, 323
  immune globulin (TIG), 167t, 322, 326, 338t
  immunization program, 324
  neonatal, 322, 323
  pathogen, 321, 572t
  vaccines, 326, 328t-330t, 332t-333t. See also DT; DTaP; T'd; T'dap; Tetanus toxoid (TT).
    characteristics and specifics of, 328t-330t, 332t-333t, 572t
    combination vaccines, 542-543, 544t-550t
    contraindications/precautions, 331-335
    immunogenicity/efficacy, 326-331
    recommendations, 324-326, 325, 335-336
      adult. See T'dap vaccines.
      children/infants. See DTaP vaccines.
      for wound management, 338t-339t
    safety, 331-335
    reportable events, 106t
    schedule, 329t, 332t, 335-336
    storage, 125t
    trade names, 328t, 332t, 544t
      Adacel (T'dap), 328t-330t
      Boostrix (T'dap), 328t-330t
      Daptacel (DTaP), 328t-330t
      Diphtheria and Tetanus Toxoids Adsorbed (DT), 332t-333t
      Infanrix (DTaP), 328t-330t
      Tenivac (Td), 332t-333t
    Tetanus and Diphtheria Toxoids Adsorbed (T'd), 332t-333t
Tetanus and Diphtheria Toxoids Adsorbed (Td), 332t-333t
Tetanus immune globulin (TIG), 167t, 322, 326
  anaphylactic reaction to, 335
  interval for live vaccines and, 167t
  precautions, 335
  for wound management, 338t-339t
Tetanus toxoid (TT), 12t, 164
Tetanus Toxoids Adsorbed (DT, Td), 332t-333t
  contraindications/precautions, 334-335
Texas Children's Hospital Center for Vaccine Awareness and Research, 560t
Th-cells (helper T lymphocytes), 23, 24-25, 32, 35
  differentiation of, 25, 258
  memory Th-cells, 26
Thimerosal, 248, 262-263. See also specific vaccines.
Thrombocytopenia, 235, 272-273, 426, 427
Ticovirimat (antiviral smallpox treatment), 489
TIG. See Tetanus immune globulin.
Timeline of vaccine development, 51
Timeliness of vaccine delivery, 73, 542
Tofacitinib, 199
Toll-like receptors (TLRs), 24
Toxins, 32
  antibodies to, 40
  cholera toxin, 315
diphtheria, 321
pertussis, 321-322
tetanus, 321
Toxoid vaccines, 12t, 17, 332t-333t, 336, 338t-339t
Toxoids, 17
Tracking systems, 130
Transplantation
  hematopoietic stem cell (HSCT), 202-203, 204t-207t, 369
  solid organ, 190t, 200-202, 201
Transportation of vaccines, 127-129
Travel, 219-225
  disease transmission/resurgence due to, 252
  diseases related to, 224-225
    cholera, 224, 225, 316
    invasive meningococcal disease, 225
    Japanese encephalitis, 224, 414
    measles, 219
    rabies, 224
    typhoid fever, 225, 504
    yellow fever, 225, 524
Hajj, 225
  international adoptees, refugees, and immigrants, 218-219, 348, 353
  proof of vaccination, 224, 225, 529
  travel medicine clinics, 220
  vaccination for, 220-225
    cholera, 224, 225, 316, 319
    hepatitis A (or IGIM), 221, 348, 353
    hepatitis B, 221, 368
Travel, continued
  influenza, 221
  Japanese encephalitis, 417
  mandatory vaccines, 225
  measles, 219, 430
  meningococcal vaccine (Saudi Arabia/Hajj), 225
  N meningitidis, 193, 225, 445
  polio, 221-224, 450, 453
  rabies, 224, 464t
  routine vaccines, being up-to-date, 220-221
  typhoid fever, 508
  Web sites on, 225
  yellow fever, 225, 528-529
Trumenba (MenB-FHbp), 173t, 435, 437-442, 438t-441t
  immunogenicity, 443
  minimum ages and intervals, 158t
  recommendations, 64t, 437, 440t, 445
  safety, 444
  storage, 124t
Tsar/Tzarina (for immunization), 119, 120t, 134
TT. See Tetanus toxoid (TT).
Tuberculin skin test (TST), 427, 489, 517, 528
Tuberculosis, 16
TViPSV. See Typhim Vi.
Twinrix (HepA-HepB), 123t, 552t-555t
Ty21a. See Vivotif.
Type 1 diabetes (T1D), 259
Typhim Vi (TViPSV), 125t, 505-509, 506t-507t
Typhoid fever, 503-510
  clinical features, 503-504
  epidemiology and transmission, 504
  immunization program, 504
  pathogen, 503, 573t
  vaccines, 504, 506t-507t, 573t
  contraindications/precautions, 508
  immunogenicity/efficacy, 505
  recommendations, 504, 509
  for travel, 225, 509
  safety, 508
  schedule, 507t
  storage, 125t
  TViPSV (Typhim Vi), 505-509, 506t-507t
  Ty21a (Vivotif), 16, 505-509, 506t-507t
Universal precautions, 110
Vaccinate Your Family, 560t
Vaccination. See also Immunization; Vaccinology.
  basic concepts, 11-52
  as civic duty, 245
  coverage goals, 73, 93
  cytotoxic T cells, implications for, 32-36
Vaccination. continued
defined, 11
federal requirements on, 102t-104t
general recommendations, 153-180
germinal center reaction, implications for, 26-32
goals, 46-48
public health impact of, 46-50, 49t, 52t
sources of information on, 238, 240, 246
triumphs of, 49t
Vaccination programs. See specific diseases.
Vaccine(s). See also Immunization; specific vaccines.
abbreviations for, 572t-573t
basic immunology of, 19-36
classification of, 12t-13t
concerns about, 231-283
correlates of protection, 36-41, 38t-39t
costs/cost-benefit analyses. See Costs.
currently available in the U.S., 12t, 12t-13t
delivery of. See Delivery of vaccines.
development of. See Vaccine development and licensure.
documentation of vaccinations received, 129
effectiveness, vs efficacy, 58
funding for. See Financing.
Holy Grail of, 20
how they work, 19-36
impact of, 48-50, 49t, 52t
inactivated, 12t, 14t, 17-18
interchangeability/different manufacturers, 163-164
licensure of. See Vaccine development and licensure.
live vaccines, 11-16, 12t-13t
live vs inactivated vaccines, 14t-15t, 35-36
National Vaccine Plan, 73, 97
necessity of, 252-253
no longer available in the U.S., 12t
omenclature, vi-vii, 572-573t
number of, and timeline of development, 50, 51
prices of. See Costs.
quality assurance, 37
recommendations regarding. See Recommendations.
resources on, 558t-562t
schedules for. See Schedules for immunization.
stockpiles of, 62, 89-90, 403
supply/shortages, 89-90
timeline of development, 51
valency, vii
virus stocks, destruction of, 46-47
Vaccine acceptance, hesitancy, and confidence, 231-235, 232, 233t
Vaccine Adverse Event Reporting System (VAERS), 79-81, 101-105
limitations of, 80
mandatory reporting to, 79, 96, 101, 103t
Vaccine confidence, 231, 233t, 242
Vaccine Confidence Project, 560t
Vaccine development and licensure, 53-62, 54
agencies involved with, 54, 66, 80
animal models, 53
Biologics License Application (BLA), 58-59
“breakthrough therapy” category, 58-59
clinical trials, 55-58, 56
costs of, 53
efficacy, 58
ethical studies of, 59
equity, 53
emergency preparedness, 62
FDA and, 53-55, 54, 68t
financial risk involved, 53
financing for, 83-88
noninferiority standard, 56, 542
package insert (PI), 59-62
postmarketing safety surveillance, 56-58, 78-83, 80
prelicensure trials, 55-58, 56
steps in, 53-59, 54
time for approval process, 55
timeline for specific vaccines, 51
VRBPAC and, 59, 66
Vaccine failure, 31, 58, 60t-61t
definitions of, 60t-61t
Vaccine Immunology, 19-36. See also Immune response.
Vaccine Information Statements (VISs), 102t, 105, 237
Vaccine infrastructure in the U.S., 53-92, 54
Defense Medical Surveillance System, 82
disease surveillance, 78
efficiency of, 58
emergency preparedness, 62, 89-90, 105, 145-147
financing, 83-88
governmental agencies, 54, 66, 558t
monitoring delivery, 73-78
monitoring safety, 78-83
policy and recommendations, 62-73
supply, 89-90
vaccine development and licensure, 53-62, 54
Vaccine Safety Net, 78-83, 80
Vaccine Injury Compensation Program (VICP), 66, 99-101. See also Vaccine Adverse Event Reporting System (VAERS).
causation, proof of, 100
children in utero covered by, 209
compensation under, 101
health care professionals’ awareness of, 96
pandemic and epidemic uses and, 489
Reportable Events Table, 106t-109t
Table injury, 100
vaccines covered, 103t (footnote e)
Vaccine Injury Table (VIT), 99-101, 106t-109t
Table injury, 100
Vaccine policy and recommendations, 62-73. See also Recommendations.
agencies involved with, 66
terms used in reference to, 68t-69t
Vaccine practice, 119-152. See also Administration of vaccines.
administration of vaccines, 135-145
coding, billing, and costs, 147-148, 150t-151t
delivery of vaccines, improving, 129-135
emergencies, 128t, 145-147
general guidelines, 119-129
handling, storage, and transport, 119-129
inventory, 119-120
signs, 119, 127
storage, 119-129, 122t-126t
transport, 127-129
Immunization Tsar/Tsarina, 119, 120t, 134
IQIP (Immunization Quality Improvement for Providers), 134
screening for contraindications, 135, 138t-140t, 241
standards for, 93-99
Vaccine-preventable diseases, 51. See also Public health.
annual deaths from, 97, 395-396, 396, 472, 494
costs of, 97
disease burden, 70
immunization goals, 46-48, 93
necessity of vaccination for, 252-253
resurgence of, 48, 248-252, 263, 324, 327, 422-426
surveillance, 78
timeline of specific vaccine development, 51
Vaccine purchasing group (VPG), 148
Vaccine recommendations. See Recommendations.
Vaccine refusal, 242-246, 244
Vaccine Safety DataLink (VSD), 81, 208
Vaccine Safety Net, 78-83, 80
ad-hoc committees and task forces, 83
Brighton Collaboration, 82
Clinical Immunization Safety Assessment (CISA) Network, 81-82, 559t
Defense Medical Surveillance System, 82
IOM Consensus Report, 83
Post-licensure Rapid Immunization Safety Monitoring (PRISM), 81
special surveillance efforts, 82
Vaccine Adverse Event Reporting System (VAERS), 79-81, 101-105
Vaccine Safety DataLink, 81
Vaccines and Related Biological Products Advisory Committee
(VRBAPAC), 59, 66
Vaccines for Children (VFC) Program, 63, 84-85, 94
common questions about, 86t-87t
keeping vaccine purchases separate, 120
vaccines covered, 72-73
Vaccines.gov, 560t
Vaccinia immune globulin, 489
Vaccinia virus, 483. See also Smallpox.
Vaccinology, 11-52. See also Immunization.
basic vaccine immunology, 19-36
classical vs reverse, 18
correlates of protection, 36-41, 38t-39t
genetics of vaccine responses/adverse events, 45-46
Vaccinology, continued
herd immunity, 41-45, 41
immunization, 11-19
public health and vaccines, 46-50, 49t, 52t
systems immunology, 18
Vaccinomics, 46
VAERS. See Vaccine Adverse Event Reporting System.
Value of Vaccination, 560t
VaqtA (HepA), 123t, 349, 350t-352t
Varicella, 511-521
chickenpox, 164, 484t-485t, 511
clinical features, 511-512
breakthrough/vaccine-modified varicella, 511-512
congenital varicella syndrome, 512
diagnosis, 484t-485t
differentiating from smallpox, 484t-485t
progressive and hemorrhagic varicella, 512
societal burden of, 70
correlates of protection, 39t
evidence of immunity, 519t
epidemiology and transmission, 512
herpes zoster (shingles) and. See Zoster
immune globulin (VarIZIG), 167t, 513, 518-520
immunization program, 513, 515-516
cost effectiveness of, 513
one-dose program, 48-50, 513
two-dose program, 513
pathogen (varicella-zoster virus, VZV), 511, 573t
attenuation of, 11-16
latency and, 511, 513, 531
reactivation of latent, 35, 511, 512, 531-532
vaccines (VAR), 513-520, 514t-515t. See also MMRV; Zoster
administration errors and remedies, 174t
contraindications/precautions, 516-517
evidence of immunity, 519t
immunogenicity/effectiveness, 513-516
interval for receipt of antibody-containing products, 164-165, 166t-168t
minimum ages and intervals, 159t, 288
recommendations, 513, 518-520
considerations in, 70
health care personnel, 217-218, 513
HIV-infected children, 182, 185-189
MMR plus VAR, preferred over MMRV, 422, 543
pregnant women and, 516-517
safety, 516-517
reportable events, 108t
schedule, 514t, 518
adults, by age, 296
adults, by medical condition, 298
children, age 0-18 years, 288
catch-up, children age 4 months-6 years, 291
catch-up, children age 7-18 years, 292
The Vaccine Handbook, 9th ed.

Varicella, continued
serial passage, 11-16
storage and transport, 126t, 129
trade name (Varivax), 514t
vs zoster vaccines (ZVL), 35, 513
VarizIG (varicella zoster immune globulin), 167t, 513, 518-520
waning immunity and, 31, 513
Varicella-zoster immune globulin. See VarizIG.
Varicella-zoster virus (VZV), reactivation of latent, 35, 511, 512, 531-532.
See also Zoster (herpes zoster; shingles).

Variola, 481, 573t. See also Smallpox.
last remaining stocks of, 47, 482
terrorism potential of, 47, 482-483
variola major, minor, and sine eruptione, 481-482

Varivax (varicella vaccine), 126t, 513-520, 514t-515t. See also Varicella, vaccines.

VarizIG (varicella zoster immune globulin), 19, 167t, 513, 518-520.
See also Varicella.
dosage, 520
for health care personnel, 218
interval for live vaccines and, 167t
for pregnant women, 209, 518

Vaxchora (cholera vaccine), 122t, 316, 318t-319t

Vaxelis (DTaP-IPV-Hib-HepB), 122t, 544t-550t

Venous thromboembolism (VTE), 386

VFC. See Vaccines for Children (VFC) Program.

Vibrio cholerae, 16, 315, 318t, 572t

VICP. See Vaccine Injury Compensation Program.

Viral interference, 541
Viruses, vs bacteria, 35

Vivotif (Ty21a), 125t, 505-509, 506t-507t

Voices for Vaccines, 560t

VRBPAC (Vaccines and Related Biological Products Advisory Committee), 59, 66

VZV (varicella-zoster virus), 511, 573t. See also Varicella

Waning immunity, 31, 48, 253, 327, 513

Warning labels, 111

Whole agent vaccines, 12t, 17

Whooping cough. See Pertussis.

Woolsorter's disease, 307

World Health Organization (WHO), 558t

X-linked agammaglobulinemia (XLA), 182, 189

Yellow fever, 523-530
clinical features, 523
epidemiology and transmission, 524
immunization program, 524
International Certificate of Vaccination or Prophylaxis, 225, 529
pathogen, 523, 573t

Yellow fever, continued
vaccine (YFV), 125t, 525-529, 526t-527t
approved sites for administration, 225, 529
contraindications/precautions, 527-528
infants, 529
immunogenicity/efficacy, 525
recommendations, 154, 524, 528-529
pregnant women, 176, 210t, 528, 529
travel, 225, 528-529
safety, 270, 525-528
vaccine-associated neurotropic disease, 527
vaccine-associated viscerotropic disease, 525-527
schedule, 526t
storage, 125t

YF-Vax. See Yellow fever, vaccine (YFV).

Zostavax (ZVL, zoster vaccine live), 65t, 534-539, 536t-538t.
See also Zoster.

Zoster (herpes zoster; shingles), 531-590. See also Varicella.
clinical features, 531-532
age and, 532
zoster sine herpete, 532
correlates of protection, 39t
costs of care during episodes, 533
epidemiology and transmission, 532-533
protection by varicella vaccination, 533
reactivation of latent VZV, 35, 511, 512, 531-532
herpes zoster (shingles), 35, 511, 531-532
as re-immunizing event, 531
immunization program, 533
cost-effectiveness of, 533
pathogen (varicella-zoster virus, VZV), 511, 531, 573t
postherpetic neuralgia (PHN) and, 531, 532
vaccines for (ZVL, RZV), 12t, 534-539, 536t-538t
administration errors and remedies, 173t, 174t
contraindications/precautions, 535, 539
immunogenicity/efficacy, 533
live-attenuated vaccine. See ZVL.
minimum ages and intervals, 159t, 165, 539
recombinant vaccine. See RZV.
recommendations, 65t, 214, 539
RZV, 534-539, 536t-538t
efficacy, 533
licensing, 533
preference for, 539
recommendations, 533
safety, 535-539
schedule, 537t, 539
adults, by age, 296
adults, by medical condition/indication, 298
storage, 125t
Zoster (herpes zoster; shingles), continued
trade names (Zostavax; Shingrix), 536t
varicella vaccine (VAR) provides protection, 533
vs varicella vaccine (VAR), 35
ZVL, 534-539, 536t-538t
licensing, 533
recommendations, 539
safety, 534-535
ZVL (zoster vaccine live). See under Zoster.